Probiotics: Difference between revisions

From WikiDemocracy
Jump to navigationJump to search
← Older edit

Kirk (talk | contribs)

7 user groups
6,886 edits
VisualWikitext
Lilly (talk | contribs)
staff, Administrators
9,983 edits
No edit summary
No edit summary
 
(7 intermediate revisions by 2 users not shown)
Line 1: Line 1:
=====Probioics=====
{{#seo:
[https://en.wikipedia.org/wiki/Probiotic by  Wikipedia]
Probiotics are live microorganisms in foods intended to improve or restore microbiota in the gut. Probiotic products include yogurt, cheese, some fermented foods, such as sourdough bread and nattō, dietary supplements, and clinical capsules containing a specific probiotic strain.


Probiotics are considered generally safe to consume, but may cause bacteria–host interactions and unwanted side effects in some cases. Many claimed health benefits, such as treating eczema or curing vaginal infections, lack substantial scientific support.
|title=Probiotics: Effective Strains, Clinical Evidence, and Health Applications


=====Probiotics=====
|description=An evidence-based overview of probiotic strains and clinical research, including Lactobacillus rhamnosus GG, Saccharomyces boulardii, Limosilactobacillus reuteri DSM 17938, Bifidobacterium longum 35624, Lactiplantibacillus plantarum 299v, and other probiotics studied for digestive, metabolic, immune, neurological, skin, and other health conditions.
[https://my.clevelandclinic.org/health/treatments/14598-probiotics by Cleveland Clinic]
Probiotics are live bacteria and yeasts that have beneficial effects on your body. These species already live in your body, along with many others. Probiotic supplements add to your existing supply of friendly microbes. They help fight off the less friendly types and boost your immunity against infections.


=====Probiotics: Usefulness and Safety=====
|keywords=probiotics, probiotic strains, Lactobacillus rhamnosus GG, LGG, Saccharomyces boulardii, Limosilactobacillus reuteri DSM 17938, Bifidobacterium longum 35624, Lactiplantibacillus plantarum 299v, Bacillus coagulans, Bifidobacterium lactis HN019, gut microbiome, antibiotic-associated diarrhea, IBS, infantile colic, constipation, probiotic research, microbiome, clinical trials
[https://www.nccih.nih.gov/health/probiotics-usefulness-and-safety by NIH]
Probiotics are live microorganisms that are intended to have health benefits when consumed or applied to the body. They can be found in yogurt and other fermented foods, dietary supplements, and beauty products. Cases of severe or fatal infections have been reported in premature infants who were given probiotics, and the U.S. Food and Drug Administration (FDA) has warned health care providers about this risk.


=====The benefits of probiotic bacteria=====
|image=https://wikidemocracy.us/images/5/5c/Science_of_Specific_Probiotic_Strains.png
[https://www.health.harvard.edu/nutrition/the-benefits-of-probiotics by Harvard Health Publishing]
|image_width=300
In a society of antibacterial warfare, who would have thought that anyone would tout the benefits of bacteria? Living microorganisms found in yogurt and other cultured foods may help improve your body's bacterial environment inside and out. They're called probiotics, a name that means "for life."


=====The power of probiotics=====
|image_height=200
[https://www.vet.cornell.edu/departments-centers-and-institutes/riney-canine-health-center/canine-health-information/power-probiotics by College of Veterinary Medicine Home]
Advertisements touting the benefits of probiotics are plentiful claim that they are a cornerstone of preventative care. Probiotics boost the healthy gut bacteria that help digest food. They are a well-known therapy for diarrhea and gastrointestinal upset. More recently, they’ve been found to counter urinary tract infections, immune system disorders and even anxiety.


=====Prebiotics versus probiotics: What’s the difference?=====
|type=article}}
[https://www.mdanderson.org/cancerwise/prebiotics-versus-probiotics-whats-the-difference.h00-159774078.html by  Erma Levy 5/2/25 MD Anderson Cancer Center]
Prebiotics and probiotics sound similar, but these nutrients benefit your gut health in different ways.
Here, I answer common prebiotic and probiotic questions I hear as a research dietitian, like the differences between the two, their health benefits and foods where they are found.


=====Probiotics=====
[[Category:Probiotics]]
[https://isappscience.org/topic/probiotics/ by ISAPP]
[[Category:Gut Microbiome]]
Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit. Probiotics can support health in different ways, such as helping your immune system function properly, aiding in digestion or increasing nutrient absorption. Additionally, some probiotics may help reduce certain digestive symptoms such as antibiotic-associated diarrhea.
[[Category:Microbiology]]
[[Category:Nutrition]]
[[Category:Gastroenterology]]
[[Category:Digestive Health]]
[[Category:Dietary Supplements]]
[[Category:Evidence-Based Medicine]]
[[Category:Clinical Research]]
[[Category:Human Microbiome]]
[[Category:Preventive Medicine]]


=====Probiotics 101: a Beginner’s Guide=====
__NOTOC__
[https://www.healthline.com/nutrition/probiotics-101 by healthline]
[[File:Science of Specific Probiotic Strains.png|thumb]]
ProbioticsTrusted Source have become all the rage, making their way into everything from dietary supplements and food additives to shampoos and acne treatments. But what, exactly, are probiotics, and why are they so beneficial for our health?


=====Food as Medicine: Probiotic Foods=====
[https://wikidemocracy.us/images/5/5b/Why_Your_Probiotic_Strain_Matters_Most.m4a Audio]
[https://www.chop.edu/health-resources/food-medicine-probiotic-foods by Children's Hospital of Philadephia]
[https://wikidemocracy.us/images/d/dc/The_Taxonomy_of_Efficacy.mp4 Video]
Probiotics are bacteria that benefit your child’s gut health. You can support your child’s gut health by including foods that contain probiotics in your family’s diet. Foods containing probiotics are also naturally full of enzymes, minerals, and vitamins. You can make many of these foods at home.


=====Optimize your metabolic & gut health=====
== Probiotics: Effective Strains, Clinical Evidence, and Health Applications ==
[https://pendulumlife.com/?srsltid=AfmBOoqzi-yHB07RSsHIcvZ6U5fHy8soiw-8-ZOM2yMNeTRipdG_iQEo by Pendulum]
Featuring strains you can't get anywhere else, including live Akkermansia, a keystone strain that's been in 3,000+ scientific publications


=====What Are Probiotics?=====
Probiotics are live microorganisms investigated for their potential to influence the intestinal and other human microbiomes and improve specific health outcomes. Clinical research increasingly demonstrates that probiotics should not be treated as a single therapeutic category. Effects observed with one organism, strain, dose, or formulation cannot automatically be assumed to apply to another.
[https://www.webmd.com/digestive-disorders/what-are-probiotics by WebMD]
Probiotics are live bacteria and yeasts that are good for you, especially your digestive system. We usually think of these as germs that cause diseases. But your body is full of bacteria, both good and bad. Probiotics are often called "good" or "helpful" bacteria because they help keep your gut healthy.


=====Promoting a Healthy Microbiome with Food and Probiotics=====
A central lesson from probiotic research is therefore the importance of identifying organisms at the strain level. Names such as ''Lacticaseibacillus rhamnosus'' GG, ''Limosilactobacillus reuteri'' DSM 17938, ''Bifidobacterium longum'' 35624, and ''Lactiplantibacillus plantarum'' 299v identify preparations that have been evaluated in specific clinical settings. Simply knowing that a product contains a Lactobacillus or Bifidobacterium species is generally insufficient to determine whether it has demonstrated clinical effectiveness.
[https://www.va.gov/WHOLEHEALTHLIBRARY/tools/promoting-healthy-microbiome-with-food-probiotics.asp by US Department of Veterans Affairs]
Foods rich in choline and carnitine (e.g., red meat and eggs) are metabolized by the intestinal microbiota to form the gas trimethylamine (TMA). TMA is converted by the liver to trimethylamine oxide (TMAO). This substance (an unhealthy postbiotic) has been strongly linked to the development of atherosclerosis and coronary artery disease.


=====International Scientific Association for Probiotics and Prebiotics=====
The research summarized here ranges from randomized controlled trials to systematic reviews, network meta-analyses, and umbrella reviews. Evidence is strongest for certain gastrointestinal applications, while research into neurological, metabolic, dermatological, autoimmune, respiratory, urogenital, and other conditions remains more variable.
[https://isappscience.org/ by ISAPP]
We advance scientific excellence in probiotics, prebiotics, synbiotics, postbiotics and fermented foods.


=====Probiotics=====
=== Strain-Specific Evidence Matters ===
[https://www.aafp.org/pubs/afp/issues/2008/1101/p1073.html by American Family Physician]
Probiotics are microorganisms with potential health benefits. They may be used to prevent and treat antibiotic-associated diarrhea and acute infectious diarrhea. They may also be effective in relieving symptoms of irritable bowel syndrome, and in treating atopic dermatitis in children. Species commonly used include Lactobacillus sp., Bifidobacterium sp., Streptococcus thermophilus, and Saccharomyces boulardii. Typical dosages vary based on the product, but common dosages range from 5 to 10 billion colony-forming units per day for children, and from 10 to 20 billion colony-forming units per day for adults. Significant adverse effects are rare, and there are no known interactions with medications.


=====Probiotics and Prebiotics=====
One of the most important developments in probiotic science is recognition that clinical effects are often strain-specific. Two microorganisms belonging to the same species may differ in their ability to survive gastrointestinal transit, interact with intestinal cells, alter microbial communities, produce metabolites, influence immune signaling, or produce measurable clinical outcomes.
[https://www.worldgastroenterology.org/guidelines/probiotics-and-prebiotics by World Gastroenterology Organisation]
Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.  Lactobacilli, along with species of Bifidobacterium, have historically been common probiotics. In 2020, the genus Lactobacillus underwent a major restructuring to better address the wide diversity of microbes assigned to the genus. Twenty-three new genera were defined, including some with well-studied probiotic species.


=====The Power of Gut Bacteria and Probiotics for Heart Health=====
This creates an important distinction between evidence for "probiotics" generally and evidence for an identified probiotic strain. Clinical studies increasingly emphasize the complete strain designation when evaluating effectiveness.
[https://www.hopkinsmedicine.org/health/wellness-and-prevention/the-power-of-gut-bacteria-and-probiotics-for-heart-health by JOHNS HOPKINS]
Did you know that you’re affected not only by what you eat but also by what the natural microorganisms in your guts metabolize after you eat? It’s true. Researchers continue to increase their understanding of how overall health is affected by gut bacteria, and in fascinating ways. Not only can these bacteria affect metabolism, immune responses and even mood, now it’s believed they may also affect heart health.


=====Probiotics=====
Several probiotic strains appearing repeatedly in the clinical literature include:
[https://www.nhs.uk/tests-and-treatments/probiotics/ by Cookies on the NHS website]
Probiotics are live bacteria and yeasts promoted as having various health benefits. They're usually added to yoghurts or taken as food supplements, and are often described as "good" or "friendly" bacteria.


=====The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic=====
* ''Lacticaseibacillus rhamnosus'' GG (LGG)
[https://www.nature.com/articles/nrgastro.2014.66 by Colin Hill, Francisco Guarner, Gregor Reid, Glenn R. Gibson, Daniel J. Merenstein, Bruno Pot, Lorenzo Morelli, Roberto Berni Canani, Harry J. Flint, Seppo Salminen, Philip C. Calder & Mary Ellen Sanders 10/6/14 naturereviews]
* ''Saccharomyces boulardii'', including CNCM I-745
An expert panel was convened in October 2013 by the International Scientific Association for Probiotics and Prebiotics (ISAPP) to discuss the field of probiotics. It is now 13 years since the definition of probiotics and 12 years after guidelines were published for regulators, scientists and industry by the Food and Agriculture Organization of the United Nations and the WHO (FAO/WHO). The FAO/WHO definition of a probiotic—“live microorganisms which when administered in adequate amounts confer a health benefit on the host”—was reinforced as relevant and sufficiently accommodating for current and anticipated applications.
* ''Limosilactobacillus reuteri'' DSM 17938
* ''Bifidobacterium longum'' 35624
* ''Lactiplantibacillus plantarum'' 299v (DSM 9843)
* ''Bacillus coagulans'' Unique IS2
* ''Bacillus coagulans'' MTCC 5856
* ''Bifidobacterium animalis'' subsp. ''lactis'' HN019
* ''Bifidobacterium animalis'' subsp. ''lactis'' BB-12
* ''Lactobacillus acidophilus'' NCFM
* ''Lactobacillus casei'' Shirota
* ''Lactobacillus crispatus'' CTV-05
* ''Lacticaseibacillus paracasei'' CNCM I-1518


=====An introduction to probiotics=====
The evidence for these strains varies considerably by condition.
[https://sncs-prod-external.mayo.edu/hometown-health/speaking-of-health/an-introduction-to-probiotics by
Allie Wergin, RDN 13/7/22 MAYO CLINIC HEALTH SYSTEM]
Probiotics are live, active microorganisms ingested to alter the gastrointestinal flora for health benefits. They often are referred to as good bacteria in the gut and compete with bad bacteria to support the body in establishing optimal digestion and aid immune function.


=====Probiotic=====
=== Antibiotic-Associated Diarrhea ===
[https://www.sciencedirect.com/topics/immunology-and-microbiology/probiotic by ScienceDirect]
Probiotic is a Greek term, where pro means benefit, and bios means life [18]. It is a bacteria-based product in which essential bacteria is used to promote health, prevent multiple diseases and pathogenic growth in aquaculture. The use of non-pathogenic bacteria can also improve dietary safety and environmental performance, which can control allergies and improve the immune system by altering host-related microorganisms [19–21]. Several gram-positive and gram-negative bacterial candidates such as Bacillus species [22–28], Vibrio species [29–31], lactic acid bacteria [32], and some other bacterial species [13,33–35] have been used as probiotics in shrimp aquaculture in recent times.


=====What Are Probiotics?=====
Antibiotic-associated diarrhea is among the better-supported clinical applications for certain probiotics. Antibiotic treatment can disrupt intestinal microbial communities, sometimes producing diarrhea during or shortly after therapy.
[https://www.youtube.com/watch?v=WUfB5D5Brwo by Cleveland Clinic YouTube]
Your body is host to both helpful and harmful yeast and bacteria. Probiotics are a group of good microbes that can be added to food and supplements that can contribute to a healthy and strong gut microbiome. They help keep your GI tract running smoothly and fight acne, UTIs and more.


=====Strengthening Knowledge and Understanding of Dietary Supplements=====
''Lacticaseibacillus rhamnosus'' GG, commonly called LGG, has been evaluated in randomized trials, systematic reviews, and meta-analyses involving both children and adults. Multiple analyses have found reductions in antibiotic-associated diarrhea, although the magnitude and certainty of benefit vary among populations and studies.
[https://ods.od.nih.gov/factsheets/Probiotics-HealthProfessional/ by NIH]
Probiotics should not be confused with prebiotics, which are typically complex carbohydrates (such as inulin and other fructo-oligosaccharides) that microorganisms in the gastrointestinal tract use as metabolic fuel [2]. Commercial products containing both prebiotics and probiotic microorganisms are often called synbiotics. Probiotics should also not be confused with postbiotics, which are preparations comprised of dead, intact, or fragmented microorganisms, with or without their metabolites, that confer a health benefit on the host [3].


=====The Potential Impact of Probiotics on Human Health: An Update on Their Health-Promoting Properties=====
The probiotic yeast ''Saccharomyces boulardii'' also has a substantial clinical literature. Meta-analyses and randomized trials have reported reductions in antibiotic-associated diarrhea among children and adults. The strain CNCM I-745 is specifically identified in some clinical literature.
[https://www.mdpi.com/2076-2607/12/2/234 by Antonio Bevilacqua MDPI]
Probiotics, known to be live microorganisms, have been shown to improve or restore the gut microbiota, which in turn has been linked to improved health. It is believed that probiotics are the modern equivalent of a panacea, with claims that they may treat or prevent different diseases both in children and adults (e.g., from colic in babies to cardiovascular disease, respiratory infection, and cancer in adults).


=====Prebiotics & Probiotics=====
These findings also illustrate why probiotic recommendations should specify the organism or strain rather than simply suggesting an unspecified probiotic supplement.
[https://gutscharity.org.uk/advice-and-information/health-and-lifestyle/prebiotics-probiotics/ by guts UK]
Our gut’s diverse ecosystem is made up of trillions of different microbes (bacteria and other tiny organisms). This is called the gut microbiome. The microbes in our gut benefit us beyond just the gut itself. They help our immune system and affect our mental health. We’ve all heard of the benefit of prebiotics and probiotics in our diets. But do we really understand them and their differences?


=====What’s the deal with probiotics?=====
=== Infantile Colic ===
[https://www.mayoclinichealthsystem.org/hometown-health/speaking-of-health/whats-the-deal-with-probiotics by MAYO CLINIC HEALTH SYSTEM]
Often referred to as "friendly" or "good" bacteria, probiotics help keep the normal healthy balance of bacteria in your gut — specifically the lining of the gut which includes the microbiome. We are learning more and more about the body's microbiome and how to maintain the balance of bacteria already growing there in addition to adding living bacteria into your system through probiotics. A healthy gut microbiome helps with digestion, boosts the immune system, contributes to blood sugar levels, and may even influence mood and mental health.


=====Clinical Guide to Probiotic Products Available in USA=====
''Limosilactobacillus reuteri'' DSM 17938 is one of the most extensively studied probiotic strains for infantile colic.
[https://usprobioticguide.com/?utm_source=intro_pg&utm_medium=civ&utm_campaign=USA_CHART by AEProbio]
Currently, the body of evidence for probiotic interventions is growing along with popular demand for these products. There is evidence to support the use of probiotic products for a variety of indications beyond gut health, however applications and results are strain-specific. Due to frequent changes in commercial availability of probiotic strains, new published evidence, and growing research, an annual review and updates of this Clinical Guide have been conducted since 2008.
A general lack of adverse effects attributable to probiotics supports the widespread use of these products but an ongoing investigation is recommended.


=====How to get more probiotics=====
Randomized controlled trials have reported reductions in crying and fussing among breastfed infants receiving DSM 17938. An individual-participant-data meta-analysis also found reductions in crying duration and increased treatment response among breastfed infants.
[https://www.health.harvard.edu/nutrition/how-to-get-more-probiotics by Harvard Health Publishing 29/1/25]
There are two ways to get more good bacteria into your gut: fermented foods and dietary supplements. Probiotic supplements, which are typically sold over the counter, are reserved to treat specific ailments as suggested by your doctor. They are not recommended for everyday use. Plus, supplements do not have the same FDA oversight as medications do.


=====Probiotics: Potential Benefits, Known Risks, and More=====
The evidence is considerably less certain for formula-fed infants. This difference illustrates that probiotic effectiveness may depend not only on strain but also on characteristics of the population receiving it.
[https://www.everydayhealth.com/probiotics/guide/ by EVERYDAY HEALTH]
Your body is home to trillions of microorganisms that help you function at your best every day.[1] Some of these microbes are probiotics — a group of good-for-you bacteria and yeast that play a role in helping you digest food, fend off diseases, and even create vitamins.[2]


=====Probiotics=====
''Bifidobacterium animalis'' subsp. ''lactis'' BB-12 has also been investigated for infantile colic, with research reporting reductions in crying and fussing.
[https://www.healthdirect.gov.au/probiotics by healthdirect australia]
Probiotics are 'good' bacteria that live naturally in your digestive system (gut). They are part of your gut microbiome. Your gut microbiome is a collection of trillions of microorganisms living inside your gut. It includes bacteria, viruses, fungi, yeasts and other microorganisms. Your gut microbiome plays important roles in your overall physical and mental wellbeing.


=====What Happens to Your Acid Reflux When You Take Probiotics?=====
=== Irritable Bowel Syndrome ===
[https://www.verywellhealth.com/can-probiotics-help-acid-reflux-11837402 by Karen Berger, PharmD 27/10/25 very well health]
Gastroesophageal reflux (also called acid reflux, or heartburn) occurs when the contents of your stomach flow up into the esophagus. The esophagus is the tube that connects your throat to your stomach. Reflux can cause heartburn or indigestion.


=====What are probiotics and what do they do?=====
Irritable bowel syndrome is one of the most extensively studied areas of probiotic research, but it is also one of the clearest examples of heterogeneous results.
[https://www.bbcgoodfood.com/health/wellness/what-are-probiotics-and-what-do-they-do by goodFOOD]
Food is digested and absorbed in the intestinal tract. This is populated by trillions of microbes that are required for keeping the body healthy. These bacteria, yeasts and viruses can be affected by a number of aspects including use of antibiotics, age, a diet low in fibre and infective diarrhoea. When the gut is affected, probiotics may help reset the balance.


=====Do Probiotics Really Work?=====
Systematic reviews generally suggest that some probiotic strains and combinations can improve IBS symptoms, but effectiveness differs considerably among preparations. Studies vary in IBS subtype, dose, strain, duration, and outcome measurement.
[https://www.scientificamerican.com/article/do-probiotics-really-work/ by Ferris Jabr 1/7/17 SCI AM]
Walk into any grocery store, and you will likely find more than a few “probiotic” products brimming with so-called beneficial bacteria that are supposed to treat everything from constipation to obesity to depression. In addition to foods traditionally prepared with live bacterial cultures (such as yogurt and other fermented dairy products), consumers can now purchase probiotic capsules and pills, fruit juices, cereals, sausages, cookies, candy, granola bars and pet food. Indeed, the popularity of probiotics has grown so much in recent years that manufacturers have even added the microorganisms to cosmetics and mattresses.


=====Probiotics: Mayo Clinic Radio=====
==== Bifidobacterium longum 35624 ====
[https://www.youtube.com/watch?v=L7jzB6T0oDM by Mayo Clinic YouTube]
Dr. Joseph Murray, a gastroenterologist at Mayo Clinic, explains probiotics and how they work. This interview originally aired Aug. 5, 2017.


=====Probiotics=====
''Bifidobacterium longum'' 35624, historically described as ''Bifidobacterium infantis'' 35624, has been evaluated in clinical trials involving IBS.
[https://www.helpguide.org/wellness/nutrition/probiotics-health-benefits-types-and-best-sources by HelpGuide.org]
Probiotics is an umbrella term for the types of beneficial live microorganisms (or microbes) found in products such as fermented foods and yogurt. When consumed, probiotics can contribute microbes to the number that naturally live in your gut and elsewhere. This community of all microbes, such as bacteria, fungi, and viruses, is known as the microbiome.


=====What are probiotic supplements – and are they necessary?=====
Research has reported improvements in abdominal pain, bloating, bowel dysfunction, incomplete evacuation, straining, and global IBS symptoms at particular doses. Strain-specific systematic reviews continue to identify 35624 among probiotics with evidence for certain IBS outcomes.
[https://www1.racgp.org.au/newsgp/clinical/what-are-probiotic-supplements-%E2%80%93-and-are-they-nece by Nicole Dynan 18/5/18 newsGP]
Probiotics are live bacteria found naturally in the gut, as well as in select foods and supplements. When taken in adequate amounts, they provide a health benefit to the person.


=====Probiotics=====
==== Lactiplantibacillus plantarum 299v ====
[https://www.ncbi.nlm.nih.gov/books/NBK553134/ by NIH]
Probiotics are used in managing and treating a variety of disease states. They are live microorganisms that are known to help improve gut health. This activity reviews the current indications for the use of probiotics, also highlighting the few contraindications. This activity will also explain the mechanism of action and critical factors that are important for the interprofessional team in terms of treatment and management of patients with various gut disorders.


=====What are probiotics?=====
''Lactiplantibacillus plantarum'' 299v, also designated DSM 9843, has produced favorable results in several IBS trials, including reductions in abdominal pain and bloating and improvements in global symptoms.
[https://www.medicinenet.com/probiotics/article.htm by Betty Kovacs Harbolic, MS, RD 29/11/23 MedicineNet]
Probiotics are live microorganisms that are intended to have health benefits when consumed or applied to the body. The idea that bacteria are beneficial can be tough to understand. We take antibiotics to kill harmful bacterial infections and use antibacterial soaps and lotions more than ever. The wrong bacteria in the wrong place can cause problems, but the right bacteria in the right place can have benefits. This is where probiotics come in. Promoting a healthy digestive tract and a healthy immune system are their most widely studied benefits of probiotics at this time. These are also commonly known as friendly, good, or healthy bacteria. Probiotics can be supplied through foods, beverages, and dietary supplements.


=====What do probiotics do? Here's what to understand before taking them=====
The evidence is not uniform, however. At least one randomized study found no significant improvement in abdominal pain or bloating compared with placebo. Such conflicting findings reinforce the need to evaluate the complete clinical literature rather than relying on a single positive study.
[https://www.yahoo.com/lifestyle/probiotics-plus-really-benefits-taking-090157241.html?guccounter=1 by Daryl Austin, USA TODAY 24/4/24 yahoo life]
Within the world of dietary supplements, vitamins and minerals are king. But just behind vitamins and minerals such as vitamin A, vitamin C, vitamin D, calcium, iron and magnesium, exist a variety of other popular supplements known as probiotics. One 2012 National Health Interview Survey (NHIS) shows 4 million Americans taking them monthly, but more recent data shows that the global probiotic market size has grown considerably since then, reaching close to $60 billion nearly a decade later.


=====Probiotic=====
==== Bacillus coagulans Unique IS2 ====
[https://www.merriam-webster.com/dictionary/probiotic by Merriam Webstar]
In a 2024 review in Frontiers in Pharmacology scientists found probiotics may reduce inflammation and pathogenic microbes in the gut, as well as potentially improve outcomes for cognition.


=====Best Probiotic Supplements Of 2025, According To Experts=====
''Bacillus coagulans'' Unique IS2 has been studied in adults and children with IBS. Randomized trials have reported improvements in abdominal pain, bloating, stool characteristics, urgency, incomplete evacuation, and overall bowel satisfaction.
[https://www.forbes.com/health/supplements/best-probiotics/ by Sarah Davis 20/10/25 Forbes]
Not all bacteria is bad for you, and probiotics are a perfect example of that. Probiotics are living microorganisms that are valuable for your gut health, providing benefits ranging from assisting with digestion to alleviating common gastrointestinal conditions. While you can consume probiotics in fermented foods like yogurt, a supplement may provide your gut the extra boost it needs.


=====“Good” Bacteria in the Gut=====
Network meta-analysis has also identified Unique IS2 among stronger-performing probiotic interventions for certain IBS outcomes.
[https://www.uspharmacist.com/article/probiotics by US Pharmacist]
Probiotics are live microorganisms (bacteria and yeasts) available without a prescription for use as dietary supplements to treat or prevent diarrhea and other gastrointestinal conditions. Probiotics are often referred to as “good” microorganisms because they help supplement those already existing in a healthy human, but they may be lacking due to recent antibiotic use or inflammatory or infectious diarrhea. Probiotic supplements, available in capsules, powders, tablets, and liquids, or in foods such as fermented milk and yogurt, are generally safe and cause few side effects.


=====Probiotics: What You Need to Know=====
==== Bacillus coagulans MTCC 5856 ====
[https://healthmatters.nyp.org/nutrition-probiotics/ by HEALTH MATTERS]
“Probiotics are active live organisms that can help support a healthy gut microbiome and may confer health benefits,” says Dr. Carolyn Newberry, a gastroenterologist and physician nutrition specialist at NewYork-Presbyterian/Weill Cornell Medical Center. “Incorporating more probiotic-rich, fermented foods in the diet may help improve your digestive health.”


=====Probiotics for Gastrointestinal Conditions: A Summary of the Evidence=====
''Bacillus coagulans'' MTCC 5856 has been studied particularly in diarrhea-predominant IBS. A randomized placebo-controlled trial reported improvements in IBS symptoms and quality-of-life measures after supplementation.
[https://www.aafp.org/pubs/afp/issues/2017/0801/p170.html by AAFP]
Probiotics contain microorganisms, most of which are bacteria similar to the beneficial bacteria that occur naturally in the human gut. Probiotics have been widely studied in a variety of gastrointestinal diseases. The most-studied species include Lactobacillus, Bifidobacterium, and Saccharomyces. However, a lack of clear guidelines on when to use probiotics and the most effective probiotic for different gastrointestinal conditions may be confusing for family physicians and their patients.


=====Probiotics: Science vs. Hype=====
=== Constipation and Gastrointestinal Transit ===
[https://now.tufts.edu/probiotics by Tufts Now]
They’re often represented as a remedy for many different ailments, but experts across Tufts say probiotics have a few important caveats consumers should know.


=====Can a probiotic help veterans with traumatic brain injury and PTSD?=====
Several identified probiotic strains have been investigated for functional constipation and gastrointestinal transit.
[https://www.cpr.org/2025/11/09/colorado-study-probiotic-ptsd-veterans/ by Andrea Dukakis 9/11/25 CPR News]
Dr. Lisa Brenner, a clinical research psychologist at the Department of Veterans Affairs and the University of Colorado School of Medicine, leads the study. Chris Lowry, of Department of Integrative Physiology at the University of Colorado Boulder, is also involved in the study, which uses the probiotic Lactobacillus rhamnosus to treat the veterans.


=====Probiotics and gut health=====
''Bifidobacterium animalis'' subsp. ''lactis'' HN019 has been evaluated in randomized trials examining whole-gut transit time, spontaneous bowel movements, stool consistency, straining, and other constipation-related outcomes.
[https://www.bda.uk.com/resource/probiotics.html by BDA]
Although people tend to think that bacteria are harmful germs that spoil food or make you ill, there are many bacteria that are good for our health. Your gut digests and absorbs food and naturally contains trillions of microorganisms (e.g. bacteria) that are important for helping us stay healthy.


=====An introduction to probiotics=====
''Bacillus coagulans'' Unique IS2 has also been studied for functional constipation, with clinical research reporting increases in spontaneous bowel movements and reductions in constipation symptoms.
[https://www.mayoclinichealthsystem.org/hometown-health/speaking-of-health/an-introduction-to-probiotics by 
Allie Wergin, RDN 13/7/22 MAYO CLINIC HEALTH SYSTEM]
Recently, there's been a lot of conversation in the media about probiotics. As a nutritionist, I often answer questions from patients looking to know more about probiotics and their publicized health benefits. While medical science works to further understand the role the microbiome plays in your daily health, there are a few questions we can shed some light on to help you gain a better understanding of probiotics.


=====Answers to Your Questions about Probiotics=====
''Lactobacillus casei'' Shirota appears in systematic reviews of chronic constipation and has been associated in some studies with improved defecation frequency and stool consistency.
[https://www.webmd.com/diet/features/answers-to-your-questions-about-probiotics by webMD]
Probiotics are "friendly bacteria" that are similar to organisms that occur naturally in the digestive tract. Certain strains or types of probiotics have been linked to all sorts of health benefits, from helping with irritable bowel syndrome and traveler’s diarrhea to boosting the immune system. They're sometimes used with antibiotics to combat the diarrhea that may result from taking antibiotics.


=====Benefits of probiotics=====
The results across constipation studies nevertheless remain heterogeneous, and effectiveness should not be generalized to every probiotic strain.
[https://www.medicalnewstoday.com/articles/264721 by MEDICALNEWSTODAY]
Probiotics are live bacteria and yeasts present in the human digestive system and in some foods and supplements. They may benefit gastrointestinal heath, the immune system, and more.


=====How to Buy Probiotics That Work=====
=== Functional Bowel Symptoms ===
[https://www.aarp.org/health/drugs-supplements/how-to-buy-probiotics-that-work/ by Hallie Levine 9/12/22 AARP]
Chances are that you’re familiar with probiotics: They’re sailing off the shelves of drugstores and health food stores nationwide. The market for probiotic supplements in North America rose from $547 million in 2017 to more than $1 billion in 2022, according to market research company Statista. It’s predicted to rise to nearly $1.5 billion in 2027, almost tripling in just a decade.


=====5 Health Benefits of Probiotics=====
''Lactobacillus acidophilus'' NCFM has been studied in IBS and other functional bowel disorders.
[https://www.healthline.com/nutrition/8-health-benefits-of-probiotics by healthline]
When you consume probiotics, they influence the natural balance of microorganisms already living in your digestive tract, a diverse ecosystem known as your gut microbiome. Probiotics help crowd out harmful bacteria, and help inhibit inflammation, boost immunity, and produce neurotransmitters, among many other functions.


=====Everything To Know About Probiotics=====
Research involving NCFM alone or combined with ''Bifidobacterium lactis'' Bi-07 has examined abdominal pain, bloating, IBS symptom severity, and mechanisms involving gastrointestinal sensory pathways.
[https://ucfhealth.com/health-tips/everything-to-know-about-probiotics/ by UCF Health]
Not all bacteria are bad for your body. In fact, over 1,000 different species of good bacteria live in your gut and play a key role in your health and how you feel. They make up what is called the microbiome and what you feed this system is directly linked to its health. Because of that, more and more consumers are taking probiotic supplements to enhance their gut health.


=====What do vaginal probiotics do?=====
Some studies have reported improvements, particularly in bloating and symptom severity, but evidence remains less extensive than for some of the better-established gastrointestinal strains.
[https://www.health.harvard.edu/womens-health/what-do-vaginal-probiotics-do by Harvard Health Publishing]
Available as oral pills and powders, as well as suppositories meant to be inserted into the vagina, vaginal probiotics are often advertised as making women feel “cleaner” or healthier. Some ads even claim these products can prevent or treat yeast infections, bacterial vaginosis, or urinary tract infections. But while it’s possible that probiotics might help maintain a stable vaginal microbiome, and perhaps boost our defense against infections, there’s no strong evidence proving they actually do this. It’s also important to note that the FDA doesn’t regulate probiotics sold as dietary supplements, so there’s no guarantee that a product contains what it says it does.


=====What are probiotics, and how do they impact your health?=====
=== Inflammatory Bowel Disease ===
[https://robinsonmed.com/what-are-probiotics-and-how-do-they-impact-your-health/ by ROBINSON MD]
The topic of gut health is rising in popularity both in and out of medical circles, and for good reason. The more research medical professionals do, the more it becomes evident that gut health is connected to various other elements of a person’s overall wellness. With more conversations about gut health happening during and outside of doctor’s appointments, the topic of probiotics has become widely discussed. What are probiotics, and what impact can they have on gut health – and, by extension, on a person’s holistic wellness? Today, we’re taking a brief dive into the impact of probiotics on your health, including steps you can take to maintain a healthy gut microbiome. Let’s go ahead and get started.


=====What Should You Know About Probiotics?=====
Probiotics have been extensively investigated in inflammatory bowel disease, particularly ulcerative colitis.
[https://www.verywellhealth.com/probiotics-7488911 by Amber J. Tresca 8/8/24 verywewllhealth]
Probiotics are live microorganisms, including bacteria and yeasts, found in some foods, supplements, and skin care products. They may have health benefits, but when and how priobiotic foods and supplements should be used is not yet well understood by science.


=====How To Pick the Best Probiotic=====
Systematic reviews and meta-analyses suggest that certain probiotic formulations may help induce remission, maintain remission, or reduce recurrence in ulcerative colitis. Results for Crohn's disease have generally been less convincing.
[https://health.clevelandclinic.org/how-to-pick-the-best-probiotic-for-you by Cleveland Clinic 13/10/22]
If you’ve come here looking for the best probiotics for you, chances are, you understand just how important and fascinating your gut microbiome can be. With trillions of microorganisms working to break down and digest your food, you want to keep the good bacteria in your gut healthy and thriving. But trusting your gut can only take you so far — and that’s where probiotics come into play.


=====Probiotic=====
The effectiveness of probiotic interventions in inflammatory bowel disease appears strongly dependent on disease subtype and formulation. Evidence for one preparation should therefore not be generalized to all probiotics.
[https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/probiotic by ScienceDirect]
Probiotics have been defined in several ways, depending on our understanding of the mechanisms of action of their effects on health and well-being of humans. The term probiotic was coined by Lilly and Stillwell [1] to describe substances produced by one microorganism, that stimulate the growth of another, thus meaning the opposite of antibiotics. Parker [2] subsequently defined probiotics as organisms and substances that contribute to intestinal balance.


=====Probiotics: What are they and how do they work?=====
=== Liver Disease and Hepatic Encephalopathy ===
[https://abcnews.go.com/Health/probiotics-work/story?id=57669204 by Dr. Nicky Mehtani 8/9/18 abc NEWS]
Two studies published in Cell earlier this week raise concerns about the usefulness of probiotics and cast doubt on their safety, leading to apprehension among consumers, vendors, and health care providers alike. But what exactly are probiotics? Who takes them? And how do the findings from the two studies fit into our existing knowledge base? Let’s take a deeper look.


=====Everything You Need to Know About Probiotics=====
Research has examined probiotics in liver cirrhosis and complications such as minimal hepatic encephalopathy.
[https://experiencelife.lifetime.life/article/everything-you-need-to-know-about-probiotics/ by Mo Perry 27/3/20 Experience Life]
Research shows, however, that our microbiomes are becoming steadily less diverse than those of our ancestors. And since the gut houses nearly 70 percent of the immune system, this shift has been linked to rising rates of food sensitivities, autoimmune conditions, mood disorders, and digestive issues, such as irritable bowel syndrome (IBS) and leaky gut.


=====Best Probiotic Supplements=====
Meta-analyses have reported possible improvements in blood ammonia, cognitive measures, liver function, intestinal microbiota, and reversal of minimal hepatic encephalopathy. Some randomized trials have also found reductions in development of overt hepatic encephalopathy.
[https://health.usnews.com/otc/rankings/probiotic-dietary-supplements by  Lisa Jones, MA, RDN, LDN, FAND 13/5/25 US News]
Probiotics are the good-guy bacteria your gut loves, and they do way more than help you digest your meal. These mighty microbes can support everything from immunity to mood and skin health to energy levels. Whether your tummy's been off since a round of antibiotics or you're just tired of feeling bloated, probiotics might be the gut buddy you didn't know you needed.


=====Probiotics 101: What are they? And which are the best?=====
The proposed mechanisms center on interactions between the intestinal microbiome and liver, sometimes described as the gut-liver axis. Alterations in microbial metabolism and intestinal barrier function may influence compounds reaching the liver through portal circulation.
[https://www.singlecare.com/blog/probiotics-do-they-work/ by Rebecca Rovenstine 17/7/20 the CHECKUP]
Probiotics may have been gaining popularity in recent years—but believe it or not, probiotics have been around since the early 19th and 20th centuries in some fashion or another. In those times, biologists found bacteria and yeast were used in the fermentation process and linked them to positive health outcomes.  


=====Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation=====
Probiotics have also been studied in nonalcoholic fatty liver disease, with meta-analyses examining liver enzymes, metabolic measures, inflammation, and insulin resistance.
[https://pmc.ncbi.nlm.nih.gov/articles/PMC3539293/ by NIH]
Recent explorations of the human gut microbiota suggest that perturbations of microbial communities may increase predisposition to different disease phenotypes. Dietary nutrients may be converted into metabolites by intestinal microbes that serve as biologically active molecules affecting regulatory functions in the host. Probiotics may restore the composition of the gut microbiome and introduce beneficial functions to gut microbial communities, resulting in amelioration or prevention of gut inflammation and other intestinal or systemic disease phenotypes.


=====4 unexpected benefits of taking probiotics including improving depression, anxiety, and cardiovascular health=====
=== Recurrent Urinary Tract Infections and Urogenital Health ===
[https://www.businessinsider.com/reference/probiotics?r=US&IR=T by Erin Heger BUSINESS INSIDER]
Not all bacteria are bad. In fact, trillions of microorganisms, including yeasts and bacteria, live in your gut, making up what doctors call the gut microbiome. These microorganisms help your body keep certain systems running like digestion or our immune responses.


=====Probiotics=====
The urogenital microbiome is another area of probiotic research.
[https://www.webmd.com/diet/probiotics by WebMD]
Probiotics are living microorganisms that can have health benefits when you consume them in high enough amounts. These can be bacteria or yeast that are similar to helpful organisms found naturally in your body, especially in the digestive tract. You can find them in some fermented foods, like yogurt. Probiotics also have become popular supplements and food additives, most often used to promote healthy digestion.


=====Get in Touch=====
''Lactobacillus crispatus'' CTV-05 has been investigated as a possible intervention for recurrent urinary tract infection in women. Other studies have examined oral and vaginal combinations of Lactobacillus strains.
[https://probiotics.com/concierge by Probiotics.com]
You have questions. We have answers. Submit your question and one of our experts will be ready to help you find the answer.


=====Probiotics: Overview, Foods, and Benefits for Gut Health=====
Research involving recurrent urinary tract infections remains mixed, with some randomized trials reporting reductions in symptomatic recurrence and systematic reviews finding that many studies remain inconclusive.
[Probiotics: Overview, Foods, and Benefits for Gut Health by Sarah Gupta, MD 22/3/22 GoodRx]
When you swallow probiotics, they travel to your gut (intestines). In your gut, they join the community of microorganisms that already live there, called your gut microbiome.


=====Prebiotics vs. Probiotics for Gut Health=====
Probiotics have also been studied in bacterial vaginosis. Meta-analyses have compared probiotics alone, antibiotics alone, and combined antibiotic-probiotic treatment. Findings suggest possible benefit in some settings but do not establish all probiotic preparations as effective treatments.
[https://www.healthline.com/nutrition/probiotics-and-prebiotics by Medically reviewed 22/5/24 healthline]
Probiotics are beneficial bacteria, and prebiotics are food for these bacteria. Eating foods or supplements containing both can help balance your gut.


=====Probiotics - Do They Actually Do Anything? And 10 Fermented Foods You Should Eat=====
=== Respiratory and Infectious Disease ===
[https://www.youtube.com/watch?v=vUelUAicc90 by Talking With Docs YouTube]
Embark on a Health Odyssey with Talking with Docs! 🌿✨ In this illuminating episode, our dedicated physicians unravel the mystery surrounding probiotics – those tiny warriors that play a crucial role in our gut health.


=====How gut health and food can transform diabetes management and prevent disease=====
''Lacticaseibacillus paracasei'' CNCM I-1518 has been studied for common respiratory and gastrointestinal infections.
[https://www.usf.edu/news/2025/how-gut-health-and-food-can-transform-diabetes-management-and-prevent-disease.aspx by Tina Meketa 10/11/25 YouTube]
“We had no clue how to really control her diabetes,” said Yadav, professor in the USF Health Department of Neurosurgery, Brain and Spine and director and USF Center for Microbiome Research. “It made me wonder if there are other ways people like my mom can manage their health naturally.”


=====What are probiotics?=====
Systematic reviews of randomized trials suggest that certain probiotic preparations may reduce the incidence or number of common infectious illnesses. Effects on duration and severity appear less consistent.
[https://abcnews.go.com/Health/video/probiotics--57680554 by abc NEWS]
Additional Live Streams


=====Digestive Enzymes and Digestive Enzyme Supplements=====
Broader research has also examined probiotics in respiratory infections, pediatric asthma, COVID-19, and post-COVID dysbiosis. These areas remain more exploratory than the evidence supporting certain gastrointestinal applications.
[https://www.hopkinsmedicine.org/health/wellness-and-prevention/digestive-enzymes-and-digestive-enzyme-supplements by Morgan Denhard JOHNS HOPKINS]
Digestive enzyme supplements have gained popularity for their claims of treating common forms of gut irritation, heartburn and other ailments. But how do digestive enzymes work, and who really needs to add them to their diet? Morgan Denhard, a registered dietitian at Johns Hopkins Medicine, provides the answers you need.


=====Probiotics: What are they and how do they work?=====
=== Oral and Periodontal Health ===
[https://www.goodmorningamerica.com/wellness/story/probiotics-work-57669204 by Dr. Nicky Mehtani 8/9/18 GMA]
 
  Two studies published in Cell earlier this week raise concerns about the usefulness of probiotics and cast doubt on their safety, leading to apprehension among consumers, vendors, and health care providers alike. But what exactly are probiotics? Who takes them? And how do the findings from the two studies fit into our existing knowledge base? Let’s take a deeper look.
Probiotics have been investigated in dental caries, periodontal disease, gingivitis, halitosis, peri-implant disease, and the broader oral microbiome.
 
Systematic reviews and umbrella reviews have reported possible benefits for periodontal pocket depth, bleeding on probing, clinical attachment, and some microbial outcomes.
 
''Lactobacillus reuteri'' has been studied as an adjunct to scaling and root planing for periodontal disease. However, oral probiotic studies use numerous strains and delivery systems, making it difficult to identify universally effective preparations.
 
=== Allergic and Dermatological Conditions ===
 
Probiotic interventions have been investigated for atopic dermatitis, allergic rhinitis, acne, psoriasis, and other inflammatory skin and allergic disorders.
 
Studies of atopic dermatitis show that results may differ considerably among probiotic species and strains. Some systematic reviews and meta-analyses report reductions in severity scores, while others emphasize inconsistency among trials.
 
Research into allergic rhinitis likewise suggests possible improvements in symptoms or quality of life, but strain-specific systematic reviews have found that results for individual preparations are often inconclusive.
 
In acne and psoriasis, growing interest centers on possible relationships between intestinal microbes, systemic inflammation, immune activity, and skin disease—the so-called gut-skin axis. Current evidence suggests possible adjunctive roles for probiotics, but the research remains less established than for antibiotic-associated diarrhea or certain gastrointestinal disorders.
 
=== Metabolic Health, Obesity, and PCOS ===
 
Probiotics and synbiotics have been studied for obesity, metabolic syndrome, cholesterol, insulin resistance, and polycystic ovary syndrome.
 
Meta-analyses involving overweight and obese populations report small changes in body weight, BMI, waist circumference, lipid measurements, blood glucose, and other cardiovascular or metabolic markers.
 
In PCOS, randomized trials have examined insulin resistance, reproductive hormones, triglycerides, inflammation, oxidative stress, and body composition. Some favorable metabolic and hormonal changes have been reported, but findings are not sufficiently uniform to treat probiotics as a replacement for established PCOS therapies.
 
=== Neurological Health and the Gut-Brain Axis ===
 
Increasing research investigates communication between the intestinal microbiome and central nervous system, often referred to as the microbiota-gut-brain axis.
 
Probiotic interventions have been studied in Parkinson's disease, Alzheimer's disease, mild cognitive impairment, migraine, multiple sclerosis, depression, anxiety, and other neurological or psychiatric conditions.
 
In Parkinson's disease, studies have examined constipation, gastrointestinal symptoms, inflammatory markers, motor and non-motor symptoms, and quality of life.
 
Studies of Alzheimer's disease and cognitive impairment have produced mixed findings. Some analyses suggest possible improvements in cognitive performance, while others find no significant overall effect.
 
Migraine studies have also investigated probiotics alone or together with nutritional supplements, with some reports of fewer headache days or reduced severity.
 
Overall, neurological applications remain promising but substantially more preliminary than established gastrointestinal indications.
 
=== Autoimmune and Inflammatory Diseases ===
 
The intestinal microbiome has been investigated as a potential contributor to immune regulation and autoimmune disease.
 
Research summarized in the literature includes rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, psoriasis, and other inflammatory disorders.
 
Some probiotic studies report reductions in inflammatory markers or modest improvements in disease-related outcomes. However, much of this literature remains heterogeneous, and some areas—particularly systemic lupus erythematosus—include substantial preclinical rather than human clinical evidence.
 
These findings should therefore be regarded as emerging research rather than established probiotic treatment indications.
 
=== Chronic Kidney Disease and the Gut-Kidney Axis ===
 
Research into chronic kidney disease increasingly examines interactions between intestinal microorganisms, inflammation, microbial metabolites, and kidney function.
 
Probiotics and synbiotics have been investigated as possible methods of changing intestinal microbial activity and reducing production of gut-derived uremic compounds.
 
Systematic reviews have examined kidney-function markers, inflammation, metabolic products, and outcomes among patients receiving dialysis. Clinical evidence remains developing and is not yet sufficient to regard probiotics as established therapy for chronic kidney disease.
 
=== Bone Health and Menopause ===
 
Probiotics have also been investigated for bone mineral density, osteoporosis, and menopausal health.
 
Studies in postmenopausal women suggest possible effects on bone mineral density, particularly in women with osteopenia. Proposed mechanisms include altered mineral absorption, inflammation, intestinal permeability, and microbial metabolite production.
 
Research in peri- and postmenopausal women also examines vaginal microbiota, urogenital health, menopausal symptoms, and interactions with other treatments.
 
These potential uses remain adjunctive and should not be considered replacements for established prevention or treatment of osteoporosis or menopausal conditions.
 
=== Celiac Disease ===
 
The intestinal microbiome has been investigated as a possible modifier of celiac disease.
 
Research into probiotic bifidobacteria examines mechanisms involving gluten-derived peptides, intestinal barrier function, inflammation, and immune responses.
 
Some studies suggest that particular strains may influence gastrointestinal symptoms or inflammatory activity, but the evidence remains limited. A strict gluten-free diet remains the fundamental management strategy represented in the research literature.
 
=== The Importance of Evidence Quality ===
 
The probiotic literature contains randomized controlled trials, systematic reviews, meta-analyses, network meta-analyses, observational studies, mechanistic studies, and experimental research.
 
These forms of evidence should not be treated as equivalent. Systematic reviews may identify apparent benefits while simultaneously reporting high heterogeneity, small sample sizes, publication bias, inconsistent formulations, or low certainty of evidence.
 
Positive findings should therefore be interpreted according to several questions:
 
* Was the probiotic identified at the strain level?
* Was the intervention tested in randomized controlled trials?
* Was the same strain evaluated in more than one independent study?
* Was the outcome clinically meaningful?
* Was the effect replicated in systematic reviews or meta-analyses?
* Were findings consistent across studies?
* Did treatment benefit a particular subgroup rather than the entire population?
* Was the probiotic administered alone or as part of a multi-strain or synbiotic formulation?
* What dose and treatment duration were used?
* Were there clinically important adverse events?
 
These distinctions are essential when translating probiotic research into practical conclusions.
 
=== Probiotics Are Not Interchangeable ===
 
One of the strongest conclusions supported by the collected research is that the word "probiotic" is too broad to function as a meaningful description of effectiveness.
 
A clinical benefit demonstrated for ''Lacticaseibacillus rhamnosus'' GG cannot automatically be attributed to another ''Lacticaseibacillus rhamnosus'' strain. Likewise, evidence concerning ''Limosilactobacillus reuteri'' DSM 17938 does not prove that every ''L. reuteri'' product will produce the same result.
 
Multi-strain supplements introduce additional complexity. A product containing many strains is not necessarily more effective than a carefully studied single-strain product. Clinical evidence must relate as closely as possible to the actual formulation being used.
 
Consumers and clinicians therefore benefit from looking beyond broad marketing terms such as "10-strain probiotic," "50 billion CFU," or "gut health probiotic." The scientifically relevant questions are which strains are present, whether that exact strain or formulation has been studied, what condition was studied, at what dose, and with what outcome.
 
=== Areas With Comparatively Stronger Evidence ===
 
The uploaded research suggests several areas in which particular probiotic strains have comparatively substantial clinical support.
 
''Lacticaseibacillus rhamnosus'' GG and ''Saccharomyces boulardii'' have repeatedly been studied for prevention of antibiotic-associated diarrhea.
 
''Limosilactobacillus reuteri'' DSM 17938 has relatively strong evidence for reducing infantile colic symptoms among breastfed infants.
 
Several specific strains—including ''Bifidobacterium longum'' 35624, ''Lactiplantibacillus plantarum'' 299v, and certain ''Bacillus coagulans'' strains—have demonstrated benefits for particular IBS outcomes, although IBS evidence remains heterogeneous.
 
''Bifidobacterium animalis'' subsp. ''lactis'' HN019 and several other strains have been investigated for constipation and intestinal transit.
 
These examples demonstrate that the most defensible claims about probiotics are usually narrow ones: a particular strain, given at a particular dose, to a particular population, for a particular clinical outcome.
 
=== Areas Where Evidence Remains Emerging ===
 
A much larger group of possible probiotic applications remains under investigation.
 
These include neurological disorders, cognitive decline, migraine, rheumatoid arthritis, lupus, chronic kidney disease, obesity, metabolic syndrome, PCOS, osteoporosis, acne, psoriasis, respiratory disease, kidney stones, celiac disease, COVID-19, and other conditions.
 
Systematic reviews in many of these areas identify potentially favorable effects. However, positive biological signals or statistically significant changes do not necessarily establish probiotics as effective clinical treatments.
 
Many fields still require larger randomized trials, standardized strains and doses, longer follow-up, replication by independent researchers, and clearer measurements of meaningful clinical outcomes.
 
=== Conclusion ===
 
Probiotic research has evolved from the broad idea of consuming "beneficial bacteria" toward a more precise understanding in which clinical effects depend heavily on the organism, strain, formulation, dose, population, and condition being treated.
 
Some of the most convincing evidence concerns specific strains used for defined gastrointestinal indications. ''Lacticaseibacillus rhamnosus'' GG and ''Saccharomyces boulardii'' have substantial evidence for antibiotic-associated diarrhea, while ''Limosilactobacillus reuteri'' DSM 17938 has demonstrated benefits for infantile colic in breastfed infants. Particular strains of ''Bifidobacterium'', ''Lactiplantibacillus'', and ''Bacillus'' have also produced favorable results in IBS and constipation research.
 
Beyond these better-studied applications, probiotics are being investigated across a remarkable range of conditions involving metabolism, immunity, neurological function, skin disease, liver health, oral health, reproductive health, and the gut-brain, gut-liver, gut-kidney, and gut-skin axes.
 
The evidence does not support treating all probiotics as equivalent. Instead, the strongest interpretation of the research is that probiotic effectiveness is often strain-specific and indication-specific. A probiotic should therefore be judged by evidence for the exact organism or formulation and the exact clinical outcome under consideration, rather than by the general reputation of probiotics as a category.
 
__TOC__
 
===Lacticaseibacillus rhamnosus GG (LGG) — Antibiotic-Associated Diarrhea===
 
[https://pubmed.ncbi.nlm.nih.gov/29511547/ | Researchers | Journal of Clinical Gastroenterology | 2018]
A network meta-analysis involving more than 9,000 participants compares different probiotics for prevention of antibiotic-associated diarrhea. Lactobacillus rhamnosus GG had the highest probability of ranking among the most effective and best-tolerated probiotic interventions.
 
[https://pubmed.ncbi.nlm.nih.gov/30078376/ | V. Agamennone et al. | European Journal of Clinical Pharmacology | 2018]
A strain-specific analysis of probiotic preparations used to prevent antibiotic-associated diarrhea identifies seven effective formulations. Lactobacillus rhamnosus GG produced one of the strongest effects, with substantially less antibiotic-associated diarrhea than placebo.
 
[https://pubmed.ncbi.nlm.nih.gov/28827186/ | C. Mantegazza et al. | Nutrients | 2018]
A clinical review of probiotics for pediatric antibiotic-associated diarrhea finds the strongest strain-specific evidence for Lactobacillus rhamnosus GG and Saccharomyces boulardii. The authors emphasize that results obtained with these strains should not be generalized to other probiotics.
 
[https://pubmed.ncbi.nlm.nih.gov/26756877/ | Hania Szajewska et al. | Journal of Pediatric Gastroenterology and Nutrition | 2016]
Evidence-based recommendations from the European Society for Pediatric Gastroenterology, Hepatology and Nutrition identify Lactobacillus rhamnosus GG as one of the probiotic strains with sufficient evidence to recommend for preventing antibiotic-associated diarrhea in children.
 
[https://pubmed.ncbi.nlm.nih.gov/26365389/ | Hania Szajewska and Marek Kołodziej | Alimentary Pharmacology & Therapeutics | 2015]
A strain-specific systematic review and meta-analysis evaluates Lactobacillus rhamnosus GG, commonly abbreviated LGG, for prevention of antibiotic-associated diarrhea. LGG significantly reduced antibiotic-associated diarrhea in children and adults, although the certainty of evidence was rated moderate to low. This is one of the better-supported strain-specific uses of probiotics.
 
[https://pubmed.ncbi.nlm.nih.gov/24889895/ | Lynne V. McFarland | Annals of Nutrition and Metabolism | 2015]
A strain-specific review of probiotics for pediatric antibiotic-associated diarrhea finds significant preventive effects for Lactobacillus rhamnosus GG as well as Saccharomyces boulardii.
 
[https://pubmed.ncbi.nlm.nih.gov/16113542/ | Jason Hawrelak et al. | Digestive Diseases and Sciences | 2005]
A systematic review evaluates Lactobacillus rhamnosus GG specifically for preventing antibiotic-associated diarrhea. Four of six qualifying clinical trials reported a significant reduction in diarrhea risk, while another showed fewer days with antibiotic-associated diarrhea.
 
 
===Saccharomyces boulardii — Antibiotic-Associated Diarrhea===
 
[https://pubmed.ncbi.nlm.nih.gov/33844181/ | M. Storr et al. | Medizinische Klinik | 2021]
A clinical review emphasizes that prevention of antibiotic-associated diarrhea is strain-specific. The authors identify Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG as evidence-based options rather than recommending probiotics as a general category.
 
[https://pubmed.ncbi.nlm.nih.gov/26216624/ | Hania Szajewska and Marek Kołodziej | Alimentary Pharmacology & Therapeutics | 2015]
A systematic review and meta-analysis evaluates the probiotic yeast Saccharomyces boulardii specifically for antibiotic-associated diarrhea. Supplementation significantly reduced the risk of antibiotic-associated diarrhea among both children and adults.
 
[https://pubmed.ncbi.nlm.nih.gov/20458757/ | Lynne V. McFarland | World Journal of Gastroenterology | 2010]
A large systematic review examines Saccharomyces boulardii across multiple gastrointestinal disorders. Twenty-seven randomized controlled studies involving more than 5,000 participants were analyzed, with particularly strong evidence for prevention of antibiotic-associated diarrhea.
 
[https://pubmed.ncbi.nlm.nih.gov/16635227/ | Lynne V. McFarland | American Journal of Gastroenterology | 2006]
A meta-analysis evaluates probiotics for antibiotic-associated diarrhea and Clostridium difficile disease. Saccharomyces boulardii and Lactobacillus rhamnosus GG were among the probiotic interventions significantly associated with prevention of antibiotic-associated diarrhea.
 
[https://pubmed.ncbi.nlm.nih.gov/16128673/ | Hania Szajewska and Jacek Mrukowicz | Alimentary Pharmacology & Therapeutics | 2005]
A strain-focused meta-analysis of randomized controlled trials finds Saccharomyces boulardii moderately effective for preventing antibiotic-associated diarrhea in children and adults.
 
[https://pubmed.ncbi.nlm.nih.gov/15740542/ | M. Kotowska et al. | Alimentary Pharmacology & Therapeutics | 2005]
A randomized placebo-controlled trial evaluates Saccharomyces boulardii for preventing antibiotic-associated diarrhea in children. Children receiving the probiotic developed substantially less antibiotic-associated diarrhea than those receiving placebo.
 
 
===Limosilactobacillus reuteri DSM 17938 — Infantile Colic===
 
[https://pubmed.ncbi.nlm.nih.gov/29279326/ | Valerie Sung et al. | Pediatrics | 2018]
An individual-participant-data meta-analysis evaluates Lactobacillus reuteri DSM 17938 specifically for infantile colic. DSM 17938 reduced crying duration and increased treatment response among breastfed infants. Evidence was insufficient to reach the same conclusion for formula-fed infants.
 
[https://pubmed.ncbi.nlm.nih.gov/29390535/ | P. Gutiérrez-Castrellón et al. | Medicine | 2017]
A network meta-analysis compares treatments for infantile colic. Lactobacillus reuteri DSM 17938 was among the interventions associated with meaningful reductions in infant colic symptoms.
 
[https://pubmed.ncbi.nlm.nih.gov/25444531/ | K. Chau et al. | Journal of Pediatrics | 2015]
A randomized double-blind placebo-controlled Canadian trial finds that Lactobacillus reuteri DSM 17938 significantly reduces crying and fussing among breastfed infants with colic.
 
[https://pubmed.ncbi.nlm.nih.gov/25876529/ | G. L. Mi et al. | PLoS ONE | 2015]
A randomized trial examines Lactobacillus reuteri DSM 17938 for infantile colic. Supplementation reduced daily crying duration and was associated with higher parental satisfaction compared with the control treatment.
 
[https://pubmed.ncbi.nlm.nih.gov/22981952/ | Hania Szajewska et al. | Journal of Pediatrics | 2013]
A randomized controlled trial evaluates Lactobacillus reuteri DSM 17938 in exclusively or predominantly breastfed infants with colic. Infants receiving DSM 17938 experienced greater reductions in crying time than those receiving placebo.
 
[https://pubmed.ncbi.nlm.nih.gov/20713478/ | Francesco Savino et al. | Pediatrics | 2010]
A randomized controlled trial administers Lactobacillus reuteri DSM 17938 to breastfed infants with colic. A dose of 100 million CFU per day reduced crying and improved colic symptoms compared with placebo.
 
 
===Bifidobacterium longum 35624 — IBS===
 
[https://pubmed.ncbi.nlm.nih.gov/41682832/ | R. Maslennikov et al. | PubMed | 2026]
A strain-specific systematic review and meta-analysis identifies Bifidobacterium longum 35624, formerly classified as Bifidobacterium infantis 35624, among the individual probiotic strains showing efficacy for important IBS symptoms.
 
[https://pubmed.ncbi.nlm.nih.gov/19367213/ | Darren M. Brenner et al. | Reviews in Gastroenterological Disorders | 2009]
A focused review examines Bifidobacterium infantis 35624 as a treatment for IBS. Two randomized controlled trials had demonstrated improvements in individual and global IBS symptoms without an apparent increase in adverse events.
 
[https://pubmed.ncbi.nlm.nih.gov/19277023/ | Darren M. Brenner et al. | American Journal of Gastroenterology | 2009]
A systematic review of probiotics for IBS identifies Bifidobacterium infantis 35624 as one of the strains supported by appropriately designed randomized controlled studies. Trials reported improvements in abdominal pain, bloating, and bowel-related symptoms.
 
[https://pubmed.ncbi.nlm.nih.gov/16863564/ | Peter J. Whorwell et al. | American Journal of Gastroenterology | 2006]
A large randomized controlled trial evaluates Bifidobacterium infantis 35624 in women with irritable bowel syndrome. One tested dose significantly improved abdominal pain, bloating, bowel dysfunction, incomplete evacuation, straining, and global IBS symptoms compared with placebo.
 
[https://pubmed.ncbi.nlm.nih.gov/15765388/ | Liam O’Mahony et al. | Gastroenterology | 2005]
A randomized clinical trial compares Bifidobacterium infantis 35624 with another probiotic and placebo in IBS. Strain 35624 improved IBS symptoms and was associated with normalization of a measure of pro- versus anti-inflammatory immune signaling.
 
 
===Lactiplantibacillus plantarum 299v (DSM 9843) — IBS===
 
[https://pubmed.ncbi.nlm.nih.gov/33556972/ | H. Krammer et al. | Zeitschrift für Gastroenterologie | 2021]
A clinical study evaluates Lactobacillus plantarum 299v for irritable bowel syndrome. Treatment was associated with significant improvement in global IBS symptoms and quality of life.
 
[https://pubmed.ncbi.nlm.nih.gov/25194614/ | C. Stevenson et al. | Nutrition | 2014]
A randomized trial provides an important counterpoint to positive studies of strain 299v. Eight weeks of Lactobacillus plantarum 299v did not significantly improve abdominal pain or bloating compared with placebo, demonstrating that even a promising strain does not produce uniform results across trials.
 
[https://pubmed.ncbi.nlm.nih.gov/22912552/ | Philippe Ducrotté et al. | World Journal of Gastroenterology | 2012]
A randomized double-blind placebo-controlled trial evaluates Lactobacillus plantarum 299v, also designated DSM 9843, in adults with IBS. Four weeks of treatment improved overall symptoms, with particularly notable reductions in abdominal pain and bloating.
 
[https://pubmed.ncbi.nlm.nih.gov/11711768/ | K. Niedzielin et al. | European Journal of Gastroenterology & Hepatology | 2001]
An early double-blind randomized controlled trial evaluates Lactobacillus plantarum 299v in people with IBS. Participants receiving 299v reported substantially greater global improvement in IBS symptoms than those receiving placebo.
 
 
===Bacillus coagulans Unique IS2 — IBS and Functional Constipation===
 
[https://pubmed.ncbi.nlm.nih.gov/37686889/ | P. Xie et al. | Nutrients | 2023]
A strain-level network meta-analysis compares individual probiotics for IBS outcomes. Bacillus coagulans Unique IS2 ranked among the strongest-performing interventions for abdominal pain.
 
[https://pubmed.ncbi.nlm.nih.gov/30911991/ | R. S. Madempudi et al. | Beneficial Microbes | 2020]
A randomized double-blind placebo-controlled study evaluates Bacillus coagulans Unique IS2 in adults with functional constipation. Supplementation increased spontaneous bowel movements and reduced several constipation-related symptoms compared with placebo.
 
[https://pubmed.ncbi.nlm.nih.gov/31434935/ | R. S. Madempudi et al. | Scientific Reports | 2019]
A randomized double-blind placebo-controlled trial evaluates Bacillus coagulans Unique IS2 in adults with IBS. The strain produced significant improvements in abdominal pain and several other IBS symptoms compared with placebo.
 
[https://pubmed.ncbi.nlm.nih.gov/29695183/ | M. Ratna Sudha et al. | Beneficial Microbes | 2018]
A randomized placebo-controlled trial evaluates Bacillus coagulans Unique IS2 in children ages four through twelve with IBS. The strain significantly reduced pain intensity and improved abdominal discomfort, bloating, stool consistency, urgency, incomplete evacuation, and overall bowel satisfaction.
 
 
===Bacillus coagulans MTCC 5856 — Diarrhea-Predominant IBS===
 
[https://pubmed.ncbi.nlm.nih.gov/26922379/ | Muhammed Majeed et al. | Nutrition Journal | 2016]
A randomized double-blind placebo-controlled trial evaluates Bacillus coagulans MTCC 5856 in adults with diarrhea-predominant IBS. Ninety days of supplementation improved several IBS symptoms and quality-of-life measures compared with placebo.
 
 
===Bifidobacterium animalis subsp. lactis HN019 — Constipation and Gut Transit===
 
[https://pubmed.ncbi.nlm.nih.gov/39356506/ | J. Cheng et al. | American Journal of Gastroenterology | 2024]
An eight-week randomized trial further evaluates Bifidobacterium animalis subsp. lactis HN019 in adults with constipation, adding to the clinical literature concerning this strain and bowel-movement frequency.
 
[https://pubmed.ncbi.nlm.nih.gov/29227175/ | A. Ibarra et al. | Gut Microbes | 2018]
  A randomized controlled trial evaluates Bifidobacterium animalis subsp. lactis HN019 in 228 adults with functional constipation. Two daily doses were studied for effects on complete spontaneous bowel movements, stool consistency, straining, and related symptoms.
 
[https://pubmed.ncbi.nlm.nih.gov/21663486/ | P. A. Waller et al. | Scandinavian Journal of Gastroenterology | 2011]
A randomized clinical trial examines different doses of Bifidobacterium lactis HN019. Supplementation shortened whole-gut transit time and improved the frequency of gastrointestinal symptoms.
 
 
===Bifidobacterium animalis subsp. lactis BB-12 — Infantile Colic===
 
[https://pubmed.ncbi.nlm.nih.gov/34550055/ | K. Chen et al. | Nutrients | 2021]
A clinical study evaluates Bifidobacterium animalis subsp. lactis BB-12 in infants diagnosed with colic. BB-12 supplementation reduced crying and fussing.
 
 
===Lactobacillus acidophilus NCFM — IBS and Functional Bowel Symptoms===
 
[https://pubmed.ncbi.nlm.nih.gov/28082816/ | Anna Lyra et al. | World Journal of Gastroenterology | 2016]
A randomized placebo-controlled study evaluates Lactobacillus acidophilus NCFM in people with irritable bowel syndrome. NCFM supplementation was associated with improvements in IBS symptom severity in some participants.
 
[https://pubmed.ncbi.nlm.nih.gov/24853043/ | T. Ringel-Kulka et al. | Alimentary Pharmacology & Therapeutics | 2014]
A randomized clinical study examines Lactobacillus acidophilus NCFM in people with functional abdominal pain.
 
[https://pubmed.ncbi.nlm.nih.gov/21436726/ | T. Ringel-Kulka et al. | Journal of Clinical Gastroenterology | 2011]
A randomized controlled trial evaluates Lactobacillus acidophilus NCFM together with Bifidobacterium lactis Bi-07 in patients with functional bowel disorders. The probiotic treatment significantly improved bloating compared with placebo.
 
 
===Lactobacillus casei Shirota — Constipation===
 
[https://pubmed.ncbi.nlm.nih.gov/36372047/ | A. van der Schoot et al. | Clinical Nutrition | 2022]
A systematic review and meta-analysis examines individual probiotics and synbiotics for chronic constipation in adults. Lactobacillus casei Shirota was among the specifically identified strains studied.
 
[https://pubmed.ncbi.nlm.nih.gov/36570175/ | M. M. Araújo et al. | Nutrients | 2022]
A systematic review identifies Lactobacillus casei Shirota as one of the better-studied individual strains for chronic constipation.
 
[https://pubmed.ncbi.nlm.nih.gov/20039451/ | Anna Chmielewska and Hania Szajewska | World Journal of Gastroenterology | 2010]
A systematic review reports favorable adult evidence for Lactobacillus casei Shirota, particularly for defecation frequency and stool consistency.
 
 
===Lactobacillus crispatus CTV-05 — Recurrent Urinary Tract Infection===
 
[https://pubmed.ncbi.nlm.nih.gov/16827601/ | Matthew E. Falagas et al. | Drugs | 2006]
A systematic review identifies Lactobacillus crispatus CTV-05 among strains showing promising preventive effects for recurrent urinary tract infection in women.
 
 
===Lacticaseibacillus paracasei CNCM I-1518 — Respiratory and Gastrointestinal Infections===
 
[https://pubmed.ncbi.nlm.nih.gov/34200435/ | M. Strauss et al. | Frontiers in Nutrition | 2021]
A systematic review evaluates individual probiotic strains for prevention of acute respiratory tract infections. Lacticaseibacillus paracasei CNCM I-1518 is among the strains supported by randomized placebo-controlled studies.
 
[https://pubmed.ncbi.nlm.nih.gov/33182682/ | Theresa Poon et al. | Nutrients | 2020]
A systematic review and meta-analysis of nine randomized trials evaluates a fermented dairy preparation containing Lacticaseibacillus paracasei CNCM I-1518 together with yogurt cultures.
 
 
===Probiotics and Parkinson’s Disease===
 
[https://pubmed.ncbi.nlm.nih.gov/41078360/ | X. Gu et al. | PubMed | 2025]
A systematic review and meta-analysis evaluates therapies targeting the intestinal microbiota in Parkinson’s disease.
 
[https://pubmed.ncbi.nlm.nih.gov/41126787/ | V. Leta et al. | PubMed | 2025]
A clinical study evaluates a four-strain probiotic in people with Parkinson’s disease.
 
[https://pubmed.ncbi.nlm.nih.gov/39228448/ | E. S. Atak et al. | PubMed / Basic and Clinical Neuroscience | 2024]
A systematic review of randomized controlled trials evaluates potential therapeutic targets of probiotics in Parkinson’s disease.
 
[https://pubmed.ncbi.nlm.nih.gov/38705493/ | X. Jin et al. | PubMed | 2024]
A systematic review and meta-analysis evaluates probiotic supplements in Parkinson’s disease.
 
[https://pubmed.ncbi.nlm.nih.gov/38878554/ | A. M. Mincic et al. | PubMed | 2024]
A review evaluates manipulation of the intestinal microbiome in neurodegenerative disorders including Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, and amyotrophic lateral sclerosis.
 
[https://pubmed.ncbi.nlm.nih.gov/38474254/ | A. I. Beltrán-Velasco et al. | PubMed | 2024]
A systematic review examines Lactiplantibacillus plantarum as a potential intervention for neurodegenerative diseases.
 
 
===Probiotics, Alzheimer’s Disease, and Cognitive Function===
 
[https://pubmed.ncbi.nlm.nih.gov/40034358/ | S. Tripathi et al. | PubMed | 2024]
A systematic review and meta-analysis evaluates individual cognitive domains in people with mild cognitive impairment and Alzheimer’s disease.
 
[https://pubmed.ncbi.nlm.nih.gov/39678681/ | F. Zhu et al. | PubMed | 2024]
A systematic analysis examines probiotic interventions across neurodegenerative diseases.
 
[https://pubmed.ncbi.nlm.nih.gov/38641508/ | R. Mo et al. | PubMed | 2024]
A meta-analysis investigates probiotic supplementation in people with Alzheimer’s disease and mild cognitive impairment.
 
[https://pubmed.ncbi.nlm.nih.gov/27891089/ | E. Akbari et al. | Frontiers in Aging Neuroscience | 2016]
A randomized double-blind controlled trial investigates probiotic supplementation in people with Alzheimer’s disease.
 
 
===Probiotics and Polycystic Ovary Syndrome===
 
[https://pubmed.ncbi.nlm.nih.gov/39599701/ | D. M. Guevara et al. | PubMed | 2024]
A systematic review of randomized clinical trials evaluates probiotics, prebiotics, and synbiotics in women with polycystic ovary syndrome.
 
[https://pubmed.ncbi.nlm.nih.gov/38421576/ | S. Salehi et al. | PubMed | 2024]
A review examines alterations of the intestinal microbiota in polycystic ovary syndrome.
 
[https://pubmed.ncbi.nlm.nih.gov/34970669/ | S. Alesi et al. | PubMed | 2022]
A comprehensive review examines nutritional supplements and complementary therapies in PCOS.
 
[https://pubmed.ncbi.nlm.nih.gov/29532416/ | M. Samimi et al. | PubMed | 2019]
A randomized controlled trial evaluates synbiotic supplementation in women with PCOS.
 
[https://pubmed.ncbi.nlm.nih.gov/29664663/ | M. Karamali et al. | PubMed | 2018]
A randomized trial evaluates probiotic supplementation and hormonal profiles in women with PCOS.
 
[https://pubmed.ncbi.nlm.nih.gov/28142296/ | S. Ahmadi et al. | PubMed | 2017]
A clinical trial examines probiotic supplementation in women with PCOS.
 
 
===Probiotics and Liver Cirrhosis===
 
[https://pubmed.ncbi.nlm.nih.gov/39267392/ | Y. L. Zhou et al. | PubMed | 2024]
A meta-analysis evaluates probiotics for minimal hepatic encephalopathy.
 
[https://pubmed.ncbi.nlm.nih.gov/39174901/ | Y. Pan et al. | PubMed | 2024]
A systematic analysis compares probiotics, prebiotics, and synbiotics for liver-related outcomes.
 
[https://pubmed.ncbi.nlm.nih.gov/38701917/ | Researchers | PubMed | 2024]
A systematic review evaluates probiotics in cirrhosis complicated by portal hypertension.
 
[https://pubmed.ncbi.nlm.nih.gov/38618195/ | Xing Yang et al. | Frontiers in Medicine | 2024]
A systematic review and meta-analysis of 30 randomized studies evaluates probiotics in liver cirrhosis.
 
[https://pubmed.ncbi.nlm.nih.gov/37502435/ | I. D. N. Wibawa et al. | PubMed | 2023]
A systematic review and meta-analysis examines probiotics for minimal hepatic encephalopathy.
 
[https://pubmed.ncbi.nlm.nih.gov/36595801/ | L. Huang et al. | PubMed | 2022]
A review examines alterations of the intestinal microbiome in cirrhosis and the effects of probiotic supplementation.
 
[https://pubmed.ncbi.nlm.nih.gov/24246768/ | M. K. Lunia et al. | PubMed | 2014]
A randomized controlled trial investigates probiotics for preventing hepatic encephalopathy in patients with cirrhosis.
 
 
===Probiotics and Acne===
 
[https://pubmed.ncbi.nlm.nih.gov/40832719/ | H. W. Lin et al. | PubMed | 2025]
A systematic review and meta-analysis evaluates oral probiotics for acne vulgaris.
 
[https://pubmed.ncbi.nlm.nih.gov/39810881/ | I. A. M. P. Sutema et al. | PubMed | 2025]
A systematic review examines oral and topical probiotic treatments for acne and skin health.
 
[https://pubmed.ncbi.nlm.nih.gov/39269130/ | A. Podwojniak et al. | PubMed | 2025]
A systematic review examines acne and the cutaneous microbiome.
 
[https://pubmed.ncbi.nlm.nih.gov/38472474/ | A. Boby et al. | Archives of Dermatological Research | 2024]
A systematic review assesses probiotics for treating acne vulgaris.
 
[https://pubmed.ncbi.nlm.nih.gov/32266790/ | A. Goodarzi et al. | PubMed | 2020]
A review explores probiotics as adjunctive therapy for acne vulgaris.
 
 
===Probiotics and Psoriasis===
 
[https://pubmed.ncbi.nlm.nih.gov/40333159/ | Y. Gao et al. | PubMed | 2025]
A review synthesizes evidence concerning intestinal dysbiosis in psoriasis and evaluates probiotics and other microbiome-directed treatments.
 
[https://pubmed.ncbi.nlm.nih.gov/39328313/ | Y. Zhu et al. | PubMed | 2024]
A systematic review and meta-analysis evaluates probiotics as adjunctive therapy for psoriasis.
 
[https://pubmed.ncbi.nlm.nih.gov/38551321/ | K. Wei et al. | PubMed | 2024]
A systematic review and meta-analysis evaluates probiotic supplementation for psoriasis.
 
[https://pubmed.ncbi.nlm.nih.gov/34938815/ | L. Zeng et al. | PubMed | 2021]
A systematic review examines the effectiveness and safety of probiotic supplementation for psoriasis.
 
 
===Probiotics and Allergic Rhinitis===
 
[https://pubmed.ncbi.nlm.nih.gov/39421038/ | X. Luo et al. | PubMed | 2024]
A systematic review and meta-analysis evaluates probiotics for preventing and treating allergic rhinitis in children.
 
[https://pubmed.ncbi.nlm.nih.gov/35663980/ | C. Luo et al. | PubMed | 2022]
A systematic review and meta-analysis examines the effectiveness and safety of probiotics for allergic rhinitis.
 
[https://pubmed.ncbi.nlm.nih.gov/35527653/ | S. Yan et al. | PubMed | 2022]
A systematic review and meta-analysis evaluates probiotics for allergic rhinitis.
 
[https://pubmed.ncbi.nlm.nih.gov/35099301/ | K. Farahmandi et al. | PubMed | 2022]
A strain-specific systematic review evaluates probiotics for allergic rhinitis.
 
[https://pubmed.ncbi.nlm.nih.gov/25899251/ | A. E. Zajac et al. | PubMed | 2015]
A systematic review and meta-analysis evaluates probiotics in allergic rhinitis.
 
 
===Probiotics and Pediatric Asthma===
 
[https://pubmed.ncbi.nlm.nih.gov/40352259/ | D. Fan et al. | PubMed | 2025]
A systematic review evaluates probiotics, prebiotics, synbiotics, and postbiotics for pediatric asthma.
 
 
===Probiotics and COVID-19===
 
[https://pubmed.ncbi.nlm.nih.gov/41004357/ | C. H. H. Chau et al. | PubMed | 2025]
A systematic review and meta-analysis evaluates probiotics for prevention and treatment of COVID-19.
 
[https://pubmed.ncbi.nlm.nih.gov/39849406/ | N. T. Iqbal et al. | PubMed | 2025]
A review examines persistent intestinal dysbiosis associated with COVID-19 and post-COVID conditions.
 
[https://pubmed.ncbi.nlm.nih.gov/39614066/ | T. Amrouche et al. | PubMed | 2025]
A review examines probiotic and prebiotic interventions in respiratory and viral infections.
 
 
===Probiotics and Multiple Sclerosis===
 
[https://pubmed.ncbi.nlm.nih.gov/40273120/ | Z. Zangeneh et al. | PubMed | 2025]
A systematic review and meta-analysis examines probiotics in multiple sclerosis using both clinical and experimental studies.
 
 
===Probiotics and Systemic Lupus Erythematosus===
 
[https://pubmed.ncbi.nlm.nih.gov/40216660/ | L. Jin et al. | PubMed | 2025]
A review explores intestinal microbiota alterations in systemic lupus erythematosus.
 
[https://pubmed.ncbi.nlm.nih.gov/38806966/ | Rachael Chaeh-Wen Goh et al. | PubMed | 2025]
A systematic review evaluates probiotic therapy in experimental models of systemic lupus erythematosus.
 
 
===Probiotics, Osteoporosis, and Bone Health===
 
[https://pubmed.ncbi.nlm.nih.gov/40716641/ | J. N. Harini et al. | PubMed | 2025]
A systematic review evaluates probiotic supplementation and bone mineral density.
 
[https://pubmed.ncbi.nlm.nih.gov/39643654/ | A. Ticinesi et al. | PubMed | 2025]
A review examines the relationship between intestinal microbiota and bone health.
 
[https://pubmed.ncbi.nlm.nih.gov/39553313/ | F. Wang et al. | PubMed | 2024]
A systematic review and meta-analysis examines probiotic supplementation and bone health in postmenopausal women.
 
 
===Probiotics and Celiac Disease===
 
[https://pubmed.ncbi.nlm.nih.gov/40887812/ | T. C. Scherer et al. | PubMed | 2025]
A review examines mechanisms through which probiotic bifidobacteria may affect responses to gluten-derived peptides.
 
[https://pubmed.ncbi.nlm.nih.gov/40771499/ | F. Valitutti et al. | PubMed | 2025]
A review examines intestinal microbiota in celiac disease and the possibility of personalized microbiome-directed treatment.
 
 
===Probiotics and Menopausal Health===
 
[https://pubmed.ncbi.nlm.nih.gov/40639456/ | R. A. F. Andrews et al. | PubMed | 2025]
A systematic review and meta-analysis evaluates probiotics in peri- and postmenopausal women.
 
 
===Probiotics and Irritable Bowel Syndrome===
 
[https://pubmed.ncbi.nlm.nih.gov/39830577/ | B. A. Almabruk et al. | PubMed | 2024]
A systematic review and meta-analysis evaluates probiotics for irritable bowel syndrome, including abdominal symptoms and quality of life.
 
[https://pubmed.ncbi.nlm.nih.gov/39575029/ | A. Manandhar et al. | PubMed | 2024]
A systematic review examines probiotic treatment in adults with irritable bowel syndrome and inflammatory bowel disease.
 
[https://pubmed.ncbi.nlm.nih.gov/38999862/ | Y. Wu et al. | PubMed | 2024]
A network meta-analysis compares probiotics, prebiotics, synbiotics, and fecal microbiota transplantation for IBS.
 
[https://pubmed.ncbi.nlm.nih.gov/38479936/ | R. Yang et al. | PubMed | 2024]
A meta-analysis of 20 studies involving more than 3,000 patients evaluates the efficacy and safety of probiotics in IBS.
 
[https://pubmed.ncbi.nlm.nih.gov/37541528/ | V. C. Goodoory et al. | PubMed | 2023]
A large systematic review and meta-analysis evaluates individual probiotic strains and combinations for IBS.
 
[https://pubmed.ncbi.nlm.nih.gov/32317962/ | B. Li et al. | PubMed | 2020]
A systematic review and meta-analysis assesses the efficacy and safety of probiotics for IBS.
 
[https://pubmed.ncbi.nlm.nih.gov/31898645/ | J. R. Sun et al. | PubMed | 2020]
A meta-analysis examines probiotic combinations, species, and strains used for IBS.
 
 
===Probiotics and Recurrent Urinary Tract Infections===
 
[https://pubmed.ncbi.nlm.nih.gov/39095666/ | Z. Han et al. | PubMed | 2025]
A network meta-analysis evaluates non-antibiotic strategies for preventing urinary tract infections.
 
[https://pubmed.ncbi.nlm.nih.gov/38930419/ | M. Daniel et al. | PubMed | 2024]
A double-blind randomized controlled trial evaluates Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 for preventing recurrent urinary tract infections in children.
 
[https://pubmed.ncbi.nlm.nih.gov/38773400/ | E. J. Nelwan et al. | PubMed | 2024]
A meta-analysis evaluates probiotics as adjunctive treatments for several infectious diseases.
 
[https://pubmed.ncbi.nlm.nih.gov/38084984/ | V. Gupta et al. | PubMed | 2024]
A randomized controlled study examines oral and vaginal probiotic prophylaxis for recurrent urinary tract infections in women.
 
[https://pubmed.ncbi.nlm.nih.gov/35156175/ | F. J. New et al. | PubMed | 2022]
A systematic review evaluates probiotics for recurrent urinary tract infections.
 
[https://pubmed.ncbi.nlm.nih.gov/30487041/ | T. Akgül and B. Karakan | PubMed | 2018]
A review examines the relationship between vaginal and urinary microbiota and recurrent urinary tract infection.
 
 
===Probiotics and Migraine===
 
[https://pubmed.ncbi.nlm.nih.gov/41070562/ | O. Grodzka et al. | PubMed | 2025]
A clinical review examines the gut microbiota, gut-brain axis, and migraine.
 
[https://pubmed.ncbi.nlm.nih.gov/39404918/ | M. K. Talandashti et al. | PubMed | 2025]
A systematic review and meta-analysis compares several dietary supplements used for migraine prevention.
 
[https://pubmed.ncbi.nlm.nih.gov/39394141/ | S. A. Tirani et al. | PubMed | 2024]
A randomized clinical trial examines combined probiotic and vitamin D supplementation in people with migraine.
 
[https://pubmed.ncbi.nlm.nih.gov/38617394/ | H. Bazmamoum et al. | PubMed | 2024]
A clinical study evaluates probiotics as an adjunct to standard migraine treatment in children.
 
 
===Probiotics and Rheumatoid Arthritis===
 
[https://pubmed.ncbi.nlm.nih.gov/41030267/ | K. Van den Bruel et al. | PubMed | 2025]
A systematic review examines diets, dietary supplements, and probiotics in rheumatoid arthritis and related inflammatory disorders.
 
[https://pubmed.ncbi.nlm.nih.gov/40054644/ | X. E. Cheng et al. | PubMed | 2025]
A systematic review evaluates nutritional supplements and dietary interventions for rheumatoid arthritis.
 
[https://pubmed.ncbi.nlm.nih.gov/38873605/ | W. Li et al. | PubMed | 2024]
An overview of systematic reviews and meta-analyses assesses the quality of evidence supporting probiotics for rheumatoid arthritis.
 
[https://pubmed.ncbi.nlm.nih.gov/38510244/ | Y. Yang et al. | PubMed | 2024]
A review explores the intestinal microbiome in rheumatoid arthritis and discusses probiotic treatment.
 
[https://pubmed.ncbi.nlm.nih.gov/37294082/ | H. C. Blenkinsopp et al. | PubMed | 2024]
A review examines intestinal permeability, microbial imbalance, and rheumatoid arthritis.
 
[https://pubmed.ncbi.nlm.nih.gov/32771911/ | J. R. Lowe et al. | PubMed | 2020]
A systematic review evaluates formulation-specific probiotic effects in inflammatory arthritis.
 
 
===Probiotics and Chronic Kidney Disease===
 
[https://pubmed.ncbi.nlm.nih.gov/40573072/ | S. Wakino et al. | PubMed | 2025]
A review examines the kidney-gut axis in chronic kidney disease and microbiome-directed treatment strategies.
 
[https://pubmed.ncbi.nlm.nih.gov/39795549/ | K. Tsuji et al. | PubMed | 2024]
A review examines the gut-kidney axis and how intestinal dysbiosis may influence chronic kidney disease.
 
[https://pubmed.ncbi.nlm.nih.gov/39758318/ | J. Ruszkowski et al. | PubMed | 2024]
A systematic review and meta-analysis evaluates probiotic and synbiotic supplementation in chronic kidney disease.
 
[https://pubmed.ncbi.nlm.nih.gov/39723354/ | N. Stepanova et al. | PubMed | 2024]
A review focuses on probiotic interventions among people receiving peritoneal dialysis.
 
[https://pubmed.ncbi.nlm.nih.gov/39166132/ | C. Liu et al. | PubMed | 2024]
A systematic review and meta-analysis assesses probiotics and synbiotics in patients with chronic kidney disease.
 
[https://pubmed.ncbi.nlm.nih.gov/24231662/ | A. Ramezani and D. S. Raj | PubMed | 2014]
A foundational review explores alterations of the intestinal microbiome in chronic kidney disease.
 
 
===Probiotics and Periodontal Disease===
 
[https://pubmed.ncbi.nlm.nih.gov/39508204/ | C. Mendonça et al. | PubMed | 2025]
An umbrella review examines 30 systematic reviews concerning probiotics for periodontal and peri-implant diseases.
 
[https://pubmed.ncbi.nlm.nih.gov/39927018/ | N. S. Abdul et al. | PubMed | 2024]
A systematic review investigates probiotics for prevention and treatment of periodontal disease.
 
[https://pubmed.ncbi.nlm.nih.gov/39609381/ | H. Sharma et al. | Indian Journal of Dental Research | 2024]
An overview of 22 systematic reviews and meta-analyses examines probiotic supplementation for periodontal disease.
 
[https://pubmed.ncbi.nlm.nih.gov/39513100/ | H. Doucette et al. | PubMed | 2024]
A review examines how prebiotics and probiotics may affect the oral microbiome.
 
[https://pubmed.ncbi.nlm.nih.gov/39407177/ | Carlota Duarte de Mendonça et al. | BMC Oral Health | 2024]
A systematic review and network meta-analysis evaluates probiotics added to professional mechanical plaque removal for periodontitis.
 
[https://pubmed.ncbi.nlm.nih.gov/38497853/ | J. Ram et al. | PubMed | 2024]
A systematic review examines Lactobacillus reuteri as an adjunct to scaling and root planing in chronic periodontitis.
 
[https://pubmed.ncbi.nlm.nih.gov/37964394/ | L. Puzhankara et al. | Oral Diseases | 2024]
A systematic review compares probiotics with antibiotics for managing gingivitis and periodontitis.
 
 
===Probiotics, Autoimmune Disease, and Inflammation===
 
[https://pubmed.ncbi.nlm.nih.gov/41978157/ | Researchers | PubMed | 2026]
A systematic review and meta-analysis examines oral probiotic and synbiotic supplementation across autoimmune diseases.
 
[https://pubmed.ncbi.nlm.nih.gov/38765017/ | X. Wang et al. | PubMed | 2024]
A review examines the emerging relationship between intestinal microbiota and autoimmune disease.
 
[https://pubmed.ncbi.nlm.nih.gov/38475833/ | L. Zeng et al. | PubMed | 2024]
A systematic review and meta-analysis evaluates gut microbiota-based therapies across autoimmune diseases.
 
 
===Probiotics and Kidney Stones===
 
[https://pubmed.ncbi.nlm.nih.gov/38682062/ | H. Taheri et al. | PubMed | 2024]
A review examines probiotics and herbal interventions for kidney stones and nephrolithiasis.
 
 
===Probiotics and Atopic Dermatitis===
 
[https://pubmed.ncbi.nlm.nih.gov/41762435/ | Researchers | PubMed / Springer | 2026]
An umbrella review evaluates systematic reviews and meta-analyses examining probiotics for atopic dermatitis and related allergic conditions in infants and children.
 
[https://pubmed.ncbi.nlm.nih.gov/41675035/ | Researchers | Journal of Allergy and Clinical Immunology: Global | 2026]
A systematic review and meta-analysis examines randomized trials of probiotics for eczema and atopic dermatitis in children and adolescents.
 
[https://pubmed.ncbi.nlm.nih.gov/40740395/ | Researchers | Indian Journal of Dermatology | 2025]
A systematic review and meta-analysis examines probiotic supplementation for adults with atopic dermatitis.
 
[https://pubmed.ncbi.nlm.nih.gov/37706436/ | Researchers | PubMed | 2023]
A systematic review and meta-analysis evaluates probiotic supplementation in adults with atopic dermatitis.
 
[https://pubmed.ncbi.nlm.nih.gov/32524647/ | Researchers | Pediatric Allergy and Immunology | 2020]
A network meta-analysis compares different probiotic strains used to treat pediatric atopic dermatitis.
 
 
===Probiotics and Helicobacter pylori===
 
[https://pubmed.ncbi.nlm.nih.gov/41581709/ | Researchers | Microbial Pathogenesis | 2026]
A meta-analysis of 28 randomized controlled trials evaluates probiotic monotherapy for reducing Helicobacter pylori colonization without antibiotics.
 
 
===Probiotics and Oral Health===
 
[https://pubmed.ncbi.nlm.nih.gov/41969406/ | Researchers | Frontiers in Oral Health | 2026]
An umbrella review of meta-analyses examines probiotic interventions for dental and oral health.
 
[https://pubmed.ncbi.nlm.nih.gov/41331162/ | Researchers | PubMed | 2025]
A systematic review evaluates randomized clinical trials investigating probiotics for enamel demineralization and cariogenic bacteria.
 
[https://pubmed.ncbi.nlm.nih.gov/37765121/ | Researchers | PubMed | 2023]
A systematic review investigates probiotics and oral health, including dental caries, periodontal disease, halitosis, mucositis and peri-implant conditions.
 
 
===Probiotics and Obesity, Cholesterol, and Metabolic Health===
 
[https://pubmed.ncbi.nlm.nih.gov/42130343/ | Researchers | Obesity Reviews | 2026]
A systematic review and meta-analysis examines probiotic and synbiotic supplementation and lipid levels among people with overweight and obesity.
 
[https://pubmed.ncbi.nlm.nih.gov/39298907/ | Researchers | Diabetes & Metabolic Syndrome | 2024]
A systematic review and meta-analysis evaluates probiotics, prebiotics, synbiotics and other microbiome-modifying therapies for metabolic syndrome.
 
[https://pubmed.ncbi.nlm.nih.gov/34358838/ | Researchers | Clinical Nutrition | 2021]
A meta-analysis of 26 randomized controlled trials involving 1,720 participants evaluates probiotics for people with overweight or obesity.
 
[https://pubmed.ncbi.nlm.nih.gov/34237694/ | Researchers | PubMed | 2021]
A systematic review and meta-analysis examines probiotic and synbiotic supplementation in adults with metabolic syndrome.
 
[https://pubmed.ncbi.nlm.nih.gov/32860083/ | Researchers | Current Atherosclerosis Reports | 2020]
A systematic review and meta-analysis examines probiotics and cardiovascular disease risk factors.
 
[https://pubmed.ncbi.nlm.nih.gov/31118956/ | Researchers | PubMed | 2019]
A systematic review and meta-analysis examines probiotics for overweight and obesity.
 
 
===Probiotics and Fatty Liver Disease===
 
[https://pubmed.ncbi.nlm.nih.gov/38643738/ | Researchers | PubMed | 2024]
A network meta-analysis compares different probiotic combinations for nonalcoholic fatty liver disease.
 
[https://pubmed.ncbi.nlm.nih.gov/34877910/ | Researchers | Expert Review of Gastroenterology & Hepatology | 2022]
A systematic review and meta-analysis evaluates randomized controlled trials of probiotics for nonalcoholic fatty liver disease.
 
[https://pubmed.ncbi.nlm.nih.gov/24187469/ | Researchers | PubMed | 2013]
An early meta-analysis examines probiotic treatment for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
 
 
===Probiotics and Constipation===
 
[https://pubmed.ncbi.nlm.nih.gov/35745212/ | Researchers | Nutrients | 2022]
A systematic review and meta-analysis examines probiotics for constipation-predominant irritable bowel syndrome.
 
[https://pubmed.ncbi.nlm.nih.gov/29118557/ | Researchers | PubMed | 2017]
A systematic review and meta-analysis examines probiotic products for constipation in adults.
 
[https://pubmed.ncbi.nlm.nih.gov/25099542/ | Researchers | American Journal of Clinical Nutrition | 2014]
A systematic review and meta-analysis evaluates probiotics for functional constipation in adults.
 
 
===Probiotics and Bacterial Vaginosis===
 
[https://pubmed.ncbi.nlm.nih.gov/35049024/ | Researchers | PubMed | 2022]
A systematic review and meta-analysis evaluates probiotics for bacterial vaginosis.
 
[https://pubmed.ncbi.nlm.nih.gov/31562865/ | Researchers | European Journal of Pharmacology | 2019]
A systematic review and meta-analysis of 13 randomized clinical trials evaluates probiotics alone and in combination with antibiotics for bacterial vaginosis.

Latest revision as of 15:22, 15 August 2026


Audio Video

Probiotics: Effective Strains, Clinical Evidence, and Health Applications

Probiotics are live microorganisms investigated for their potential to influence the intestinal and other human microbiomes and improve specific health outcomes. Clinical research increasingly demonstrates that probiotics should not be treated as a single therapeutic category. Effects observed with one organism, strain, dose, or formulation cannot automatically be assumed to apply to another.

A central lesson from probiotic research is therefore the importance of identifying organisms at the strain level. Names such as Lacticaseibacillus rhamnosus GG, Limosilactobacillus reuteri DSM 17938, Bifidobacterium longum 35624, and Lactiplantibacillus plantarum 299v identify preparations that have been evaluated in specific clinical settings. Simply knowing that a product contains a Lactobacillus or Bifidobacterium species is generally insufficient to determine whether it has demonstrated clinical effectiveness.

The research summarized here ranges from randomized controlled trials to systematic reviews, network meta-analyses, and umbrella reviews. Evidence is strongest for certain gastrointestinal applications, while research into neurological, metabolic, dermatological, autoimmune, respiratory, urogenital, and other conditions remains more variable.

Strain-Specific Evidence Matters

One of the most important developments in probiotic science is recognition that clinical effects are often strain-specific. Two microorganisms belonging to the same species may differ in their ability to survive gastrointestinal transit, interact with intestinal cells, alter microbial communities, produce metabolites, influence immune signaling, or produce measurable clinical outcomes.

This creates an important distinction between evidence for "probiotics" generally and evidence for an identified probiotic strain. Clinical studies increasingly emphasize the complete strain designation when evaluating effectiveness.

Several probiotic strains appearing repeatedly in the clinical literature include:

  • Lacticaseibacillus rhamnosus GG (LGG)
  • Saccharomyces boulardii, including CNCM I-745
  • Limosilactobacillus reuteri DSM 17938
  • Bifidobacterium longum 35624
  • Lactiplantibacillus plantarum 299v (DSM 9843)
  • Bacillus coagulans Unique IS2
  • Bacillus coagulans MTCC 5856
  • Bifidobacterium animalis subsp. lactis HN019
  • Bifidobacterium animalis subsp. lactis BB-12
  • Lactobacillus acidophilus NCFM
  • Lactobacillus casei Shirota
  • Lactobacillus crispatus CTV-05
  • Lacticaseibacillus paracasei CNCM I-1518

The evidence for these strains varies considerably by condition.

Antibiotic-Associated Diarrhea

Antibiotic-associated diarrhea is among the better-supported clinical applications for certain probiotics. Antibiotic treatment can disrupt intestinal microbial communities, sometimes producing diarrhea during or shortly after therapy.

Lacticaseibacillus rhamnosus GG, commonly called LGG, has been evaluated in randomized trials, systematic reviews, and meta-analyses involving both children and adults. Multiple analyses have found reductions in antibiotic-associated diarrhea, although the magnitude and certainty of benefit vary among populations and studies.

The probiotic yeast Saccharomyces boulardii also has a substantial clinical literature. Meta-analyses and randomized trials have reported reductions in antibiotic-associated diarrhea among children and adults. The strain CNCM I-745 is specifically identified in some clinical literature.

These findings also illustrate why probiotic recommendations should specify the organism or strain rather than simply suggesting an unspecified probiotic supplement.

Infantile Colic

Limosilactobacillus reuteri DSM 17938 is one of the most extensively studied probiotic strains for infantile colic.

Randomized controlled trials have reported reductions in crying and fussing among breastfed infants receiving DSM 17938. An individual-participant-data meta-analysis also found reductions in crying duration and increased treatment response among breastfed infants.

The evidence is considerably less certain for formula-fed infants. This difference illustrates that probiotic effectiveness may depend not only on strain but also on characteristics of the population receiving it.

Bifidobacterium animalis subsp. lactis BB-12 has also been investigated for infantile colic, with research reporting reductions in crying and fussing.

Irritable Bowel Syndrome

Irritable bowel syndrome is one of the most extensively studied areas of probiotic research, but it is also one of the clearest examples of heterogeneous results.

Systematic reviews generally suggest that some probiotic strains and combinations can improve IBS symptoms, but effectiveness differs considerably among preparations. Studies vary in IBS subtype, dose, strain, duration, and outcome measurement.

Bifidobacterium longum 35624

Bifidobacterium longum 35624, historically described as Bifidobacterium infantis 35624, has been evaluated in clinical trials involving IBS.

Research has reported improvements in abdominal pain, bloating, bowel dysfunction, incomplete evacuation, straining, and global IBS symptoms at particular doses. Strain-specific systematic reviews continue to identify 35624 among probiotics with evidence for certain IBS outcomes.

Lactiplantibacillus plantarum 299v

Lactiplantibacillus plantarum 299v, also designated DSM 9843, has produced favorable results in several IBS trials, including reductions in abdominal pain and bloating and improvements in global symptoms.

The evidence is not uniform, however. At least one randomized study found no significant improvement in abdominal pain or bloating compared with placebo. Such conflicting findings reinforce the need to evaluate the complete clinical literature rather than relying on a single positive study.

Bacillus coagulans Unique IS2

Bacillus coagulans Unique IS2 has been studied in adults and children with IBS. Randomized trials have reported improvements in abdominal pain, bloating, stool characteristics, urgency, incomplete evacuation, and overall bowel satisfaction.

Network meta-analysis has also identified Unique IS2 among stronger-performing probiotic interventions for certain IBS outcomes.

Bacillus coagulans MTCC 5856

Bacillus coagulans MTCC 5856 has been studied particularly in diarrhea-predominant IBS. A randomized placebo-controlled trial reported improvements in IBS symptoms and quality-of-life measures after supplementation.

Constipation and Gastrointestinal Transit

Several identified probiotic strains have been investigated for functional constipation and gastrointestinal transit.

Bifidobacterium animalis subsp. lactis HN019 has been evaluated in randomized trials examining whole-gut transit time, spontaneous bowel movements, stool consistency, straining, and other constipation-related outcomes.

Bacillus coagulans Unique IS2 has also been studied for functional constipation, with clinical research reporting increases in spontaneous bowel movements and reductions in constipation symptoms.

Lactobacillus casei Shirota appears in systematic reviews of chronic constipation and has been associated in some studies with improved defecation frequency and stool consistency.

The results across constipation studies nevertheless remain heterogeneous, and effectiveness should not be generalized to every probiotic strain.

Functional Bowel Symptoms

Lactobacillus acidophilus NCFM has been studied in IBS and other functional bowel disorders.

Research involving NCFM alone or combined with Bifidobacterium lactis Bi-07 has examined abdominal pain, bloating, IBS symptom severity, and mechanisms involving gastrointestinal sensory pathways.

Some studies have reported improvements, particularly in bloating and symptom severity, but evidence remains less extensive than for some of the better-established gastrointestinal strains.

Inflammatory Bowel Disease

Probiotics have been extensively investigated in inflammatory bowel disease, particularly ulcerative colitis.

Systematic reviews and meta-analyses suggest that certain probiotic formulations may help induce remission, maintain remission, or reduce recurrence in ulcerative colitis. Results for Crohn's disease have generally been less convincing.

The effectiveness of probiotic interventions in inflammatory bowel disease appears strongly dependent on disease subtype and formulation. Evidence for one preparation should therefore not be generalized to all probiotics.

Liver Disease and Hepatic Encephalopathy

Research has examined probiotics in liver cirrhosis and complications such as minimal hepatic encephalopathy.

Meta-analyses have reported possible improvements in blood ammonia, cognitive measures, liver function, intestinal microbiota, and reversal of minimal hepatic encephalopathy. Some randomized trials have also found reductions in development of overt hepatic encephalopathy.

The proposed mechanisms center on interactions between the intestinal microbiome and liver, sometimes described as the gut-liver axis. Alterations in microbial metabolism and intestinal barrier function may influence compounds reaching the liver through portal circulation.

Probiotics have also been studied in nonalcoholic fatty liver disease, with meta-analyses examining liver enzymes, metabolic measures, inflammation, and insulin resistance.

Recurrent Urinary Tract Infections and Urogenital Health

The urogenital microbiome is another area of probiotic research.

Lactobacillus crispatus CTV-05 has been investigated as a possible intervention for recurrent urinary tract infection in women. Other studies have examined oral and vaginal combinations of Lactobacillus strains.

Research involving recurrent urinary tract infections remains mixed, with some randomized trials reporting reductions in symptomatic recurrence and systematic reviews finding that many studies remain inconclusive.

Probiotics have also been studied in bacterial vaginosis. Meta-analyses have compared probiotics alone, antibiotics alone, and combined antibiotic-probiotic treatment. Findings suggest possible benefit in some settings but do not establish all probiotic preparations as effective treatments.

Respiratory and Infectious Disease

Lacticaseibacillus paracasei CNCM I-1518 has been studied for common respiratory and gastrointestinal infections.

Systematic reviews of randomized trials suggest that certain probiotic preparations may reduce the incidence or number of common infectious illnesses. Effects on duration and severity appear less consistent.

Broader research has also examined probiotics in respiratory infections, pediatric asthma, COVID-19, and post-COVID dysbiosis. These areas remain more exploratory than the evidence supporting certain gastrointestinal applications.

Oral and Periodontal Health

Probiotics have been investigated in dental caries, periodontal disease, gingivitis, halitosis, peri-implant disease, and the broader oral microbiome.

Systematic reviews and umbrella reviews have reported possible benefits for periodontal pocket depth, bleeding on probing, clinical attachment, and some microbial outcomes.

Lactobacillus reuteri has been studied as an adjunct to scaling and root planing for periodontal disease. However, oral probiotic studies use numerous strains and delivery systems, making it difficult to identify universally effective preparations.

Allergic and Dermatological Conditions

Probiotic interventions have been investigated for atopic dermatitis, allergic rhinitis, acne, psoriasis, and other inflammatory skin and allergic disorders.

Studies of atopic dermatitis show that results may differ considerably among probiotic species and strains. Some systematic reviews and meta-analyses report reductions in severity scores, while others emphasize inconsistency among trials.

Research into allergic rhinitis likewise suggests possible improvements in symptoms or quality of life, but strain-specific systematic reviews have found that results for individual preparations are often inconclusive.

In acne and psoriasis, growing interest centers on possible relationships between intestinal microbes, systemic inflammation, immune activity, and skin disease—the so-called gut-skin axis. Current evidence suggests possible adjunctive roles for probiotics, but the research remains less established than for antibiotic-associated diarrhea or certain gastrointestinal disorders.

Metabolic Health, Obesity, and PCOS

Probiotics and synbiotics have been studied for obesity, metabolic syndrome, cholesterol, insulin resistance, and polycystic ovary syndrome.

Meta-analyses involving overweight and obese populations report small changes in body weight, BMI, waist circumference, lipid measurements, blood glucose, and other cardiovascular or metabolic markers.

In PCOS, randomized trials have examined insulin resistance, reproductive hormones, triglycerides, inflammation, oxidative stress, and body composition. Some favorable metabolic and hormonal changes have been reported, but findings are not sufficiently uniform to treat probiotics as a replacement for established PCOS therapies.

Neurological Health and the Gut-Brain Axis

Increasing research investigates communication between the intestinal microbiome and central nervous system, often referred to as the microbiota-gut-brain axis.

Probiotic interventions have been studied in Parkinson's disease, Alzheimer's disease, mild cognitive impairment, migraine, multiple sclerosis, depression, anxiety, and other neurological or psychiatric conditions.

In Parkinson's disease, studies have examined constipation, gastrointestinal symptoms, inflammatory markers, motor and non-motor symptoms, and quality of life.

Studies of Alzheimer's disease and cognitive impairment have produced mixed findings. Some analyses suggest possible improvements in cognitive performance, while others find no significant overall effect.

Migraine studies have also investigated probiotics alone or together with nutritional supplements, with some reports of fewer headache days or reduced severity.

Overall, neurological applications remain promising but substantially more preliminary than established gastrointestinal indications.

Autoimmune and Inflammatory Diseases

The intestinal microbiome has been investigated as a potential contributor to immune regulation and autoimmune disease.

Research summarized in the literature includes rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, psoriasis, and other inflammatory disorders.

Some probiotic studies report reductions in inflammatory markers or modest improvements in disease-related outcomes. However, much of this literature remains heterogeneous, and some areas—particularly systemic lupus erythematosus—include substantial preclinical rather than human clinical evidence.

These findings should therefore be regarded as emerging research rather than established probiotic treatment indications.

Chronic Kidney Disease and the Gut-Kidney Axis

Research into chronic kidney disease increasingly examines interactions between intestinal microorganisms, inflammation, microbial metabolites, and kidney function.

Probiotics and synbiotics have been investigated as possible methods of changing intestinal microbial activity and reducing production of gut-derived uremic compounds.

Systematic reviews have examined kidney-function markers, inflammation, metabolic products, and outcomes among patients receiving dialysis. Clinical evidence remains developing and is not yet sufficient to regard probiotics as established therapy for chronic kidney disease.

Bone Health and Menopause

Probiotics have also been investigated for bone mineral density, osteoporosis, and menopausal health.

Studies in postmenopausal women suggest possible effects on bone mineral density, particularly in women with osteopenia. Proposed mechanisms include altered mineral absorption, inflammation, intestinal permeability, and microbial metabolite production.

Research in peri- and postmenopausal women also examines vaginal microbiota, urogenital health, menopausal symptoms, and interactions with other treatments.

These potential uses remain adjunctive and should not be considered replacements for established prevention or treatment of osteoporosis or menopausal conditions.

Celiac Disease

The intestinal microbiome has been investigated as a possible modifier of celiac disease.

Research into probiotic bifidobacteria examines mechanisms involving gluten-derived peptides, intestinal barrier function, inflammation, and immune responses.

Some studies suggest that particular strains may influence gastrointestinal symptoms or inflammatory activity, but the evidence remains limited. A strict gluten-free diet remains the fundamental management strategy represented in the research literature.

The Importance of Evidence Quality

The probiotic literature contains randomized controlled trials, systematic reviews, meta-analyses, network meta-analyses, observational studies, mechanistic studies, and experimental research.

These forms of evidence should not be treated as equivalent. Systematic reviews may identify apparent benefits while simultaneously reporting high heterogeneity, small sample sizes, publication bias, inconsistent formulations, or low certainty of evidence.

Positive findings should therefore be interpreted according to several questions:

  • Was the probiotic identified at the strain level?
  • Was the intervention tested in randomized controlled trials?
  • Was the same strain evaluated in more than one independent study?
  • Was the outcome clinically meaningful?
  • Was the effect replicated in systematic reviews or meta-analyses?
  • Were findings consistent across studies?
  • Did treatment benefit a particular subgroup rather than the entire population?
  • Was the probiotic administered alone or as part of a multi-strain or synbiotic formulation?
  • What dose and treatment duration were used?
  • Were there clinically important adverse events?

These distinctions are essential when translating probiotic research into practical conclusions.

Probiotics Are Not Interchangeable

One of the strongest conclusions supported by the collected research is that the word "probiotic" is too broad to function as a meaningful description of effectiveness.

A clinical benefit demonstrated for Lacticaseibacillus rhamnosus GG cannot automatically be attributed to another Lacticaseibacillus rhamnosus strain. Likewise, evidence concerning Limosilactobacillus reuteri DSM 17938 does not prove that every L. reuteri product will produce the same result.

Multi-strain supplements introduce additional complexity. A product containing many strains is not necessarily more effective than a carefully studied single-strain product. Clinical evidence must relate as closely as possible to the actual formulation being used.

Consumers and clinicians therefore benefit from looking beyond broad marketing terms such as "10-strain probiotic," "50 billion CFU," or "gut health probiotic." The scientifically relevant questions are which strains are present, whether that exact strain or formulation has been studied, what condition was studied, at what dose, and with what outcome.

Areas With Comparatively Stronger Evidence

The uploaded research suggests several areas in which particular probiotic strains have comparatively substantial clinical support.

Lacticaseibacillus rhamnosus GG and Saccharomyces boulardii have repeatedly been studied for prevention of antibiotic-associated diarrhea.

Limosilactobacillus reuteri DSM 17938 has relatively strong evidence for reducing infantile colic symptoms among breastfed infants.

Several specific strains—including Bifidobacterium longum 35624, Lactiplantibacillus plantarum 299v, and certain Bacillus coagulans strains—have demonstrated benefits for particular IBS outcomes, although IBS evidence remains heterogeneous.

Bifidobacterium animalis subsp. lactis HN019 and several other strains have been investigated for constipation and intestinal transit.

These examples demonstrate that the most defensible claims about probiotics are usually narrow ones: a particular strain, given at a particular dose, to a particular population, for a particular clinical outcome.

Areas Where Evidence Remains Emerging

A much larger group of possible probiotic applications remains under investigation.

These include neurological disorders, cognitive decline, migraine, rheumatoid arthritis, lupus, chronic kidney disease, obesity, metabolic syndrome, PCOS, osteoporosis, acne, psoriasis, respiratory disease, kidney stones, celiac disease, COVID-19, and other conditions.

Systematic reviews in many of these areas identify potentially favorable effects. However, positive biological signals or statistically significant changes do not necessarily establish probiotics as effective clinical treatments.

Many fields still require larger randomized trials, standardized strains and doses, longer follow-up, replication by independent researchers, and clearer measurements of meaningful clinical outcomes.

Conclusion

Probiotic research has evolved from the broad idea of consuming "beneficial bacteria" toward a more precise understanding in which clinical effects depend heavily on the organism, strain, formulation, dose, population, and condition being treated.

Some of the most convincing evidence concerns specific strains used for defined gastrointestinal indications. Lacticaseibacillus rhamnosus GG and Saccharomyces boulardii have substantial evidence for antibiotic-associated diarrhea, while Limosilactobacillus reuteri DSM 17938 has demonstrated benefits for infantile colic in breastfed infants. Particular strains of Bifidobacterium, Lactiplantibacillus, and Bacillus have also produced favorable results in IBS and constipation research.

Beyond these better-studied applications, probiotics are being investigated across a remarkable range of conditions involving metabolism, immunity, neurological function, skin disease, liver health, oral health, reproductive health, and the gut-brain, gut-liver, gut-kidney, and gut-skin axes.

The evidence does not support treating all probiotics as equivalent. Instead, the strongest interpretation of the research is that probiotic effectiveness is often strain-specific and indication-specific. A probiotic should therefore be judged by evidence for the exact organism or formulation and the exact clinical outcome under consideration, rather than by the general reputation of probiotics as a category.

Lacticaseibacillus rhamnosus GG (LGG) — Antibiotic-Associated Diarrhea

| Researchers | Journal of Clinical Gastroenterology | 2018 

A network meta-analysis involving more than 9,000 participants compares different probiotics for prevention of antibiotic-associated diarrhea. Lactobacillus rhamnosus GG had the highest probability of ranking among the most effective and best-tolerated probiotic interventions.

| V. Agamennone et al. | European Journal of Clinical Pharmacology | 2018 

A strain-specific analysis of probiotic preparations used to prevent antibiotic-associated diarrhea identifies seven effective formulations. Lactobacillus rhamnosus GG produced one of the strongest effects, with substantially less antibiotic-associated diarrhea than placebo.

| C. Mantegazza et al. | Nutrients | 2018 

A clinical review of probiotics for pediatric antibiotic-associated diarrhea finds the strongest strain-specific evidence for Lactobacillus rhamnosus GG and Saccharomyces boulardii. The authors emphasize that results obtained with these strains should not be generalized to other probiotics.

| Hania Szajewska et al. | Journal of Pediatric Gastroenterology and Nutrition | 2016 

Evidence-based recommendations from the European Society for Pediatric Gastroenterology, Hepatology and Nutrition identify Lactobacillus rhamnosus GG as one of the probiotic strains with sufficient evidence to recommend for preventing antibiotic-associated diarrhea in children.

| Hania Szajewska and Marek Kołodziej | Alimentary Pharmacology & Therapeutics | 2015 

A strain-specific systematic review and meta-analysis evaluates Lactobacillus rhamnosus GG, commonly abbreviated LGG, for prevention of antibiotic-associated diarrhea. LGG significantly reduced antibiotic-associated diarrhea in children and adults, although the certainty of evidence was rated moderate to low. This is one of the better-supported strain-specific uses of probiotics.

| Lynne V. McFarland | Annals of Nutrition and Metabolism | 2015 

A strain-specific review of probiotics for pediatric antibiotic-associated diarrhea finds significant preventive effects for Lactobacillus rhamnosus GG as well as Saccharomyces boulardii.

| Jason Hawrelak et al. | Digestive Diseases and Sciences | 2005 

A systematic review evaluates Lactobacillus rhamnosus GG specifically for preventing antibiotic-associated diarrhea. Four of six qualifying clinical trials reported a significant reduction in diarrhea risk, while another showed fewer days with antibiotic-associated diarrhea.


Saccharomyces boulardii — Antibiotic-Associated Diarrhea

| M. Storr et al. | Medizinische Klinik | 2021 

A clinical review emphasizes that prevention of antibiotic-associated diarrhea is strain-specific. The authors identify Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG as evidence-based options rather than recommending probiotics as a general category.

| Hania Szajewska and Marek Kołodziej | Alimentary Pharmacology & Therapeutics | 2015 

A systematic review and meta-analysis evaluates the probiotic yeast Saccharomyces boulardii specifically for antibiotic-associated diarrhea. Supplementation significantly reduced the risk of antibiotic-associated diarrhea among both children and adults.

| Lynne V. McFarland | World Journal of Gastroenterology | 2010 

A large systematic review examines Saccharomyces boulardii across multiple gastrointestinal disorders. Twenty-seven randomized controlled studies involving more than 5,000 participants were analyzed, with particularly strong evidence for prevention of antibiotic-associated diarrhea.

| Lynne V. McFarland | American Journal of Gastroenterology | 2006 

A meta-analysis evaluates probiotics for antibiotic-associated diarrhea and Clostridium difficile disease. Saccharomyces boulardii and Lactobacillus rhamnosus GG were among the probiotic interventions significantly associated with prevention of antibiotic-associated diarrhea.

| Hania Szajewska and Jacek Mrukowicz | Alimentary Pharmacology & Therapeutics | 2005 

A strain-focused meta-analysis of randomized controlled trials finds Saccharomyces boulardii moderately effective for preventing antibiotic-associated diarrhea in children and adults.

| M. Kotowska et al. | Alimentary Pharmacology & Therapeutics | 2005 

A randomized placebo-controlled trial evaluates Saccharomyces boulardii for preventing antibiotic-associated diarrhea in children. Children receiving the probiotic developed substantially less antibiotic-associated diarrhea than those receiving placebo.


Limosilactobacillus reuteri DSM 17938 — Infantile Colic

| Valerie Sung et al. | Pediatrics | 2018 

An individual-participant-data meta-analysis evaluates Lactobacillus reuteri DSM 17938 specifically for infantile colic. DSM 17938 reduced crying duration and increased treatment response among breastfed infants. Evidence was insufficient to reach the same conclusion for formula-fed infants.

| P. Gutiérrez-Castrellón et al. | Medicine | 2017 

A network meta-analysis compares treatments for infantile colic. Lactobacillus reuteri DSM 17938 was among the interventions associated with meaningful reductions in infant colic symptoms.

| K. Chau et al. | Journal of Pediatrics | 2015 

A randomized double-blind placebo-controlled Canadian trial finds that Lactobacillus reuteri DSM 17938 significantly reduces crying and fussing among breastfed infants with colic.

| G. L. Mi et al. | PLoS ONE | 2015 

A randomized trial examines Lactobacillus reuteri DSM 17938 for infantile colic. Supplementation reduced daily crying duration and was associated with higher parental satisfaction compared with the control treatment.

| Hania Szajewska et al. | Journal of Pediatrics | 2013 

A randomized controlled trial evaluates Lactobacillus reuteri DSM 17938 in exclusively or predominantly breastfed infants with colic. Infants receiving DSM 17938 experienced greater reductions in crying time than those receiving placebo.

| Francesco Savino et al. | Pediatrics | 2010 

A randomized controlled trial administers Lactobacillus reuteri DSM 17938 to breastfed infants with colic. A dose of 100 million CFU per day reduced crying and improved colic symptoms compared with placebo.


Bifidobacterium longum 35624 — IBS

| R. Maslennikov et al. | PubMed | 2026 

A strain-specific systematic review and meta-analysis identifies Bifidobacterium longum 35624, formerly classified as Bifidobacterium infantis 35624, among the individual probiotic strains showing efficacy for important IBS symptoms.

| Darren M. Brenner et al. | Reviews in Gastroenterological Disorders | 2009 

A focused review examines Bifidobacterium infantis 35624 as a treatment for IBS. Two randomized controlled trials had demonstrated improvements in individual and global IBS symptoms without an apparent increase in adverse events.

| Darren M. Brenner et al. | American Journal of Gastroenterology | 2009 

A systematic review of probiotics for IBS identifies Bifidobacterium infantis 35624 as one of the strains supported by appropriately designed randomized controlled studies. Trials reported improvements in abdominal pain, bloating, and bowel-related symptoms.

| Peter J. Whorwell et al. | American Journal of Gastroenterology | 2006 

A large randomized controlled trial evaluates Bifidobacterium infantis 35624 in women with irritable bowel syndrome. One tested dose significantly improved abdominal pain, bloating, bowel dysfunction, incomplete evacuation, straining, and global IBS symptoms compared with placebo.

| Liam O’Mahony et al. | Gastroenterology | 2005 

A randomized clinical trial compares Bifidobacterium infantis 35624 with another probiotic and placebo in IBS. Strain 35624 improved IBS symptoms and was associated with normalization of a measure of pro- versus anti-inflammatory immune signaling.


Lactiplantibacillus plantarum 299v (DSM 9843) — IBS

| H. Krammer et al. | Zeitschrift für Gastroenterologie | 2021 

A clinical study evaluates Lactobacillus plantarum 299v for irritable bowel syndrome. Treatment was associated with significant improvement in global IBS symptoms and quality of life.

| C. Stevenson et al. | Nutrition | 2014 

A randomized trial provides an important counterpoint to positive studies of strain 299v. Eight weeks of Lactobacillus plantarum 299v did not significantly improve abdominal pain or bloating compared with placebo, demonstrating that even a promising strain does not produce uniform results across trials.

| Philippe Ducrotté et al. | World Journal of Gastroenterology | 2012 

A randomized double-blind placebo-controlled trial evaluates Lactobacillus plantarum 299v, also designated DSM 9843, in adults with IBS. Four weeks of treatment improved overall symptoms, with particularly notable reductions in abdominal pain and bloating.

| K. Niedzielin et al. | European Journal of Gastroenterology & Hepatology | 2001 

An early double-blind randomized controlled trial evaluates Lactobacillus plantarum 299v in people with IBS. Participants receiving 299v reported substantially greater global improvement in IBS symptoms than those receiving placebo.


Bacillus coagulans Unique IS2 — IBS and Functional Constipation

| P. Xie et al. | Nutrients | 2023 

A strain-level network meta-analysis compares individual probiotics for IBS outcomes. Bacillus coagulans Unique IS2 ranked among the strongest-performing interventions for abdominal pain.

| R. S. Madempudi et al. | Beneficial Microbes | 2020 

A randomized double-blind placebo-controlled study evaluates Bacillus coagulans Unique IS2 in adults with functional constipation. Supplementation increased spontaneous bowel movements and reduced several constipation-related symptoms compared with placebo.

| R. S. Madempudi et al. | Scientific Reports | 2019 

A randomized double-blind placebo-controlled trial evaluates Bacillus coagulans Unique IS2 in adults with IBS. The strain produced significant improvements in abdominal pain and several other IBS symptoms compared with placebo.

| M. Ratna Sudha et al. | Beneficial Microbes | 2018 

A randomized placebo-controlled trial evaluates Bacillus coagulans Unique IS2 in children ages four through twelve with IBS. The strain significantly reduced pain intensity and improved abdominal discomfort, bloating, stool consistency, urgency, incomplete evacuation, and overall bowel satisfaction.


Bacillus coagulans MTCC 5856 — Diarrhea-Predominant IBS

| Muhammed Majeed et al. | Nutrition Journal | 2016 

A randomized double-blind placebo-controlled trial evaluates Bacillus coagulans MTCC 5856 in adults with diarrhea-predominant IBS. Ninety days of supplementation improved several IBS symptoms and quality-of-life measures compared with placebo.


Bifidobacterium animalis subsp. lactis HN019 — Constipation and Gut Transit

| J. Cheng et al. | American Journal of Gastroenterology | 2024 

An eight-week randomized trial further evaluates Bifidobacterium animalis subsp. lactis HN019 in adults with constipation, adding to the clinical literature concerning this strain and bowel-movement frequency.

| A. Ibarra et al. | Gut Microbes | 2018 

A randomized controlled trial evaluates Bifidobacterium animalis subsp. lactis HN019 in 228 adults with functional constipation. Two daily doses were studied for effects on complete spontaneous bowel movements, stool consistency, straining, and related symptoms.

| P. A. Waller et al. | Scandinavian Journal of Gastroenterology | 2011 

A randomized clinical trial examines different doses of Bifidobacterium lactis HN019. Supplementation shortened whole-gut transit time and improved the frequency of gastrointestinal symptoms.


Bifidobacterium animalis subsp. lactis BB-12 — Infantile Colic

| K. Chen et al. | Nutrients | 2021 

A clinical study evaluates Bifidobacterium animalis subsp. lactis BB-12 in infants diagnosed with colic. BB-12 supplementation reduced crying and fussing.


Lactobacillus acidophilus NCFM — IBS and Functional Bowel Symptoms

| Anna Lyra et al. | World Journal of Gastroenterology | 2016 

A randomized placebo-controlled study evaluates Lactobacillus acidophilus NCFM in people with irritable bowel syndrome. NCFM supplementation was associated with improvements in IBS symptom severity in some participants.

| T. Ringel-Kulka et al. | Alimentary Pharmacology & Therapeutics | 2014 

A randomized clinical study examines Lactobacillus acidophilus NCFM in people with functional abdominal pain.

| T. Ringel-Kulka et al. | Journal of Clinical Gastroenterology | 2011 

A randomized controlled trial evaluates Lactobacillus acidophilus NCFM together with Bifidobacterium lactis Bi-07 in patients with functional bowel disorders. The probiotic treatment significantly improved bloating compared with placebo.


Lactobacillus casei Shirota — Constipation

| A. van der Schoot et al. | Clinical Nutrition | 2022 

A systematic review and meta-analysis examines individual probiotics and synbiotics for chronic constipation in adults. Lactobacillus casei Shirota was among the specifically identified strains studied.

| M. M. Araújo et al. | Nutrients | 2022 

A systematic review identifies Lactobacillus casei Shirota as one of the better-studied individual strains for chronic constipation.

| Anna Chmielewska and Hania Szajewska | World Journal of Gastroenterology | 2010 

A systematic review reports favorable adult evidence for Lactobacillus casei Shirota, particularly for defecation frequency and stool consistency.


Lactobacillus crispatus CTV-05 — Recurrent Urinary Tract Infection

| Matthew E. Falagas et al. | Drugs | 2006 

A systematic review identifies Lactobacillus crispatus CTV-05 among strains showing promising preventive effects for recurrent urinary tract infection in women.


Lacticaseibacillus paracasei CNCM I-1518 — Respiratory and Gastrointestinal Infections

| M. Strauss et al. | Frontiers in Nutrition | 2021 

A systematic review evaluates individual probiotic strains for prevention of acute respiratory tract infections. Lacticaseibacillus paracasei CNCM I-1518 is among the strains supported by randomized placebo-controlled studies.

| Theresa Poon et al. | Nutrients | 2020 

A systematic review and meta-analysis of nine randomized trials evaluates a fermented dairy preparation containing Lacticaseibacillus paracasei CNCM I-1518 together with yogurt cultures.


Probiotics and Parkinson’s Disease

| X. Gu et al. | PubMed | 2025 

A systematic review and meta-analysis evaluates therapies targeting the intestinal microbiota in Parkinson’s disease.

| V. Leta et al. | PubMed | 2025 

A clinical study evaluates a four-strain probiotic in people with Parkinson’s disease.

| E. S. Atak et al. | PubMed / Basic and Clinical Neuroscience | 2024 

A systematic review of randomized controlled trials evaluates potential therapeutic targets of probiotics in Parkinson’s disease.

| X. Jin et al. | PubMed | 2024 

A systematic review and meta-analysis evaluates probiotic supplements in Parkinson’s disease.

| A. M. Mincic et al. | PubMed | 2024 

A review evaluates manipulation of the intestinal microbiome in neurodegenerative disorders including Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, and amyotrophic lateral sclerosis.

| A. I. Beltrán-Velasco et al. | PubMed | 2024 

A systematic review examines Lactiplantibacillus plantarum as a potential intervention for neurodegenerative diseases.


Probiotics, Alzheimer’s Disease, and Cognitive Function

| S. Tripathi et al. | PubMed | 2024 

A systematic review and meta-analysis evaluates individual cognitive domains in people with mild cognitive impairment and Alzheimer’s disease.

| F. Zhu et al. | PubMed | 2024 

A systematic analysis examines probiotic interventions across neurodegenerative diseases.

| R. Mo et al. | PubMed | 2024 

A meta-analysis investigates probiotic supplementation in people with Alzheimer’s disease and mild cognitive impairment.

| E. Akbari et al. | Frontiers in Aging Neuroscience | 2016 

A randomized double-blind controlled trial investigates probiotic supplementation in people with Alzheimer’s disease.


Probiotics and Polycystic Ovary Syndrome

| D. M. Guevara et al. | PubMed | 2024 

A systematic review of randomized clinical trials evaluates probiotics, prebiotics, and synbiotics in women with polycystic ovary syndrome.

| S. Salehi et al. | PubMed | 2024 

A review examines alterations of the intestinal microbiota in polycystic ovary syndrome.

| S. Alesi et al. | PubMed | 2022 

A comprehensive review examines nutritional supplements and complementary therapies in PCOS.

| M. Samimi et al. | PubMed | 2019 

A randomized controlled trial evaluates synbiotic supplementation in women with PCOS.

| M. Karamali et al. | PubMed | 2018 

A randomized trial evaluates probiotic supplementation and hormonal profiles in women with PCOS.

| S. Ahmadi et al. | PubMed | 2017 

A clinical trial examines probiotic supplementation in women with PCOS.


Probiotics and Liver Cirrhosis

| Y. L. Zhou et al. | PubMed | 2024 

A meta-analysis evaluates probiotics for minimal hepatic encephalopathy.

| Y. Pan et al. | PubMed | 2024 

A systematic analysis compares probiotics, prebiotics, and synbiotics for liver-related outcomes.

| Researchers | PubMed | 2024 

A systematic review evaluates probiotics in cirrhosis complicated by portal hypertension.

| Xing Yang et al. | Frontiers in Medicine | 2024 

A systematic review and meta-analysis of 30 randomized studies evaluates probiotics in liver cirrhosis.

| I. D. N. Wibawa et al. | PubMed | 2023 

A systematic review and meta-analysis examines probiotics for minimal hepatic encephalopathy.

| L. Huang et al. | PubMed | 2022 

A review examines alterations of the intestinal microbiome in cirrhosis and the effects of probiotic supplementation.

| M. K. Lunia et al. | PubMed | 2014 

A randomized controlled trial investigates probiotics for preventing hepatic encephalopathy in patients with cirrhosis.


Probiotics and Acne

| H. W. Lin et al. | PubMed | 2025 

A systematic review and meta-analysis evaluates oral probiotics for acne vulgaris.

| I. A. M. P. Sutema et al. | PubMed | 2025 

A systematic review examines oral and topical probiotic treatments for acne and skin health.

| A. Podwojniak et al. | PubMed | 2025 

A systematic review examines acne and the cutaneous microbiome.

| A. Boby et al. | Archives of Dermatological Research | 2024 

A systematic review assesses probiotics for treating acne vulgaris.

| A. Goodarzi et al. | PubMed | 2020 

A review explores probiotics as adjunctive therapy for acne vulgaris.


Probiotics and Psoriasis

| Y. Gao et al. | PubMed | 2025 

A review synthesizes evidence concerning intestinal dysbiosis in psoriasis and evaluates probiotics and other microbiome-directed treatments.

| Y. Zhu et al. | PubMed | 2024 

A systematic review and meta-analysis evaluates probiotics as adjunctive therapy for psoriasis.

| K. Wei et al. | PubMed | 2024 

A systematic review and meta-analysis evaluates probiotic supplementation for psoriasis.

| L. Zeng et al. | PubMed | 2021 

A systematic review examines the effectiveness and safety of probiotic supplementation for psoriasis.


Probiotics and Allergic Rhinitis

| X. Luo et al. | PubMed | 2024 

A systematic review and meta-analysis evaluates probiotics for preventing and treating allergic rhinitis in children.

| C. Luo et al. | PubMed | 2022 

A systematic review and meta-analysis examines the effectiveness and safety of probiotics for allergic rhinitis.

| S. Yan et al. | PubMed | 2022 

A systematic review and meta-analysis evaluates probiotics for allergic rhinitis.

| K. Farahmandi et al. | PubMed | 2022 

A strain-specific systematic review evaluates probiotics for allergic rhinitis.

| A. E. Zajac et al. | PubMed | 2015 

A systematic review and meta-analysis evaluates probiotics in allergic rhinitis.


Probiotics and Pediatric Asthma

| D. Fan et al. | PubMed | 2025 

A systematic review evaluates probiotics, prebiotics, synbiotics, and postbiotics for pediatric asthma.


Probiotics and COVID-19

| C. H. H. Chau et al. | PubMed | 2025 

A systematic review and meta-analysis evaluates probiotics for prevention and treatment of COVID-19.

| N. T. Iqbal et al. | PubMed | 2025 

A review examines persistent intestinal dysbiosis associated with COVID-19 and post-COVID conditions.

| T. Amrouche et al. | PubMed | 2025 

A review examines probiotic and prebiotic interventions in respiratory and viral infections.


Probiotics and Multiple Sclerosis

| Z. Zangeneh et al. | PubMed | 2025 

A systematic review and meta-analysis examines probiotics in multiple sclerosis using both clinical and experimental studies.


Probiotics and Systemic Lupus Erythematosus

| L. Jin et al. | PubMed | 2025 

A review explores intestinal microbiota alterations in systemic lupus erythematosus.

| Rachael Chaeh-Wen Goh et al. | PubMed | 2025 

A systematic review evaluates probiotic therapy in experimental models of systemic lupus erythematosus.


Probiotics, Osteoporosis, and Bone Health

| J. N. Harini et al. | PubMed | 2025 

A systematic review evaluates probiotic supplementation and bone mineral density.

| A. Ticinesi et al. | PubMed | 2025 

A review examines the relationship between intestinal microbiota and bone health.

| F. Wang et al. | PubMed | 2024 

A systematic review and meta-analysis examines probiotic supplementation and bone health in postmenopausal women.


Probiotics and Celiac Disease

| T. C. Scherer et al. | PubMed | 2025 

A review examines mechanisms through which probiotic bifidobacteria may affect responses to gluten-derived peptides.

| F. Valitutti et al. | PubMed | 2025 

A review examines intestinal microbiota in celiac disease and the possibility of personalized microbiome-directed treatment.


Probiotics and Menopausal Health

| R. A. F. Andrews et al. | PubMed | 2025 

A systematic review and meta-analysis evaluates probiotics in peri- and postmenopausal women.


Probiotics and Irritable Bowel Syndrome

| B. A. Almabruk et al. | PubMed | 2024 

A systematic review and meta-analysis evaluates probiotics for irritable bowel syndrome, including abdominal symptoms and quality of life.

| A. Manandhar et al. | PubMed | 2024 

A systematic review examines probiotic treatment in adults with irritable bowel syndrome and inflammatory bowel disease.

| Y. Wu et al. | PubMed | 2024 

A network meta-analysis compares probiotics, prebiotics, synbiotics, and fecal microbiota transplantation for IBS.

| R. Yang et al. | PubMed | 2024 

A meta-analysis of 20 studies involving more than 3,000 patients evaluates the efficacy and safety of probiotics in IBS.

| V. C. Goodoory et al. | PubMed | 2023 

A large systematic review and meta-analysis evaluates individual probiotic strains and combinations for IBS.

| B. Li et al. | PubMed | 2020 

A systematic review and meta-analysis assesses the efficacy and safety of probiotics for IBS.

| J. R. Sun et al. | PubMed | 2020 

A meta-analysis examines probiotic combinations, species, and strains used for IBS.


Probiotics and Recurrent Urinary Tract Infections

| Z. Han et al. | PubMed | 2025 

A network meta-analysis evaluates non-antibiotic strategies for preventing urinary tract infections.

| M. Daniel et al. | PubMed | 2024 

A double-blind randomized controlled trial evaluates Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 for preventing recurrent urinary tract infections in children.

| E. J. Nelwan et al. | PubMed | 2024 

A meta-analysis evaluates probiotics as adjunctive treatments for several infectious diseases.

| V. Gupta et al. | PubMed | 2024 

A randomized controlled study examines oral and vaginal probiotic prophylaxis for recurrent urinary tract infections in women.

| F. J. New et al. | PubMed | 2022 

A systematic review evaluates probiotics for recurrent urinary tract infections.

| T. Akgül and B. Karakan | PubMed | 2018 

A review examines the relationship between vaginal and urinary microbiota and recurrent urinary tract infection.


Probiotics and Migraine

| O. Grodzka et al. | PubMed | 2025 

A clinical review examines the gut microbiota, gut-brain axis, and migraine.

| M. K. Talandashti et al. | PubMed | 2025 

A systematic review and meta-analysis compares several dietary supplements used for migraine prevention.

| S. A. Tirani et al. | PubMed | 2024 

A randomized clinical trial examines combined probiotic and vitamin D supplementation in people with migraine.

| H. Bazmamoum et al. | PubMed | 2024 

A clinical study evaluates probiotics as an adjunct to standard migraine treatment in children.


Probiotics and Rheumatoid Arthritis

| K. Van den Bruel et al. | PubMed | 2025 

A systematic review examines diets, dietary supplements, and probiotics in rheumatoid arthritis and related inflammatory disorders.

| X. E. Cheng et al. | PubMed | 2025 

A systematic review evaluates nutritional supplements and dietary interventions for rheumatoid arthritis.

| W. Li et al. | PubMed | 2024 

An overview of systematic reviews and meta-analyses assesses the quality of evidence supporting probiotics for rheumatoid arthritis.

| Y. Yang et al. | PubMed | 2024 

A review explores the intestinal microbiome in rheumatoid arthritis and discusses probiotic treatment.

| H. C. Blenkinsopp et al. | PubMed | 2024 

A review examines intestinal permeability, microbial imbalance, and rheumatoid arthritis.

| J. R. Lowe et al. | PubMed | 2020 

A systematic review evaluates formulation-specific probiotic effects in inflammatory arthritis.


Probiotics and Chronic Kidney Disease

| S. Wakino et al. | PubMed | 2025 

A review examines the kidney-gut axis in chronic kidney disease and microbiome-directed treatment strategies.

| K. Tsuji et al. | PubMed | 2024 

A review examines the gut-kidney axis and how intestinal dysbiosis may influence chronic kidney disease.

| J. Ruszkowski et al. | PubMed | 2024 

A systematic review and meta-analysis evaluates probiotic and synbiotic supplementation in chronic kidney disease.

| N. Stepanova et al. | PubMed | 2024 

A review focuses on probiotic interventions among people receiving peritoneal dialysis.

| C. Liu et al. | PubMed | 2024 

A systematic review and meta-analysis assesses probiotics and synbiotics in patients with chronic kidney disease.

| A. Ramezani and D. S. Raj | PubMed | 2014 

A foundational review explores alterations of the intestinal microbiome in chronic kidney disease.


Probiotics and Periodontal Disease

| C. Mendonça et al. | PubMed | 2025 

An umbrella review examines 30 systematic reviews concerning probiotics for periodontal and peri-implant diseases.

| N. S. Abdul et al. | PubMed | 2024 

A systematic review investigates probiotics for prevention and treatment of periodontal disease.

| H. Sharma et al. | Indian Journal of Dental Research | 2024 

An overview of 22 systematic reviews and meta-analyses examines probiotic supplementation for periodontal disease.

| H. Doucette et al. | PubMed | 2024 

A review examines how prebiotics and probiotics may affect the oral microbiome.

| Carlota Duarte de Mendonça et al. | BMC Oral Health | 2024 

A systematic review and network meta-analysis evaluates probiotics added to professional mechanical plaque removal for periodontitis.

| J. Ram et al. | PubMed | 2024 

A systematic review examines Lactobacillus reuteri as an adjunct to scaling and root planing in chronic periodontitis.

| L. Puzhankara et al. | Oral Diseases | 2024 

A systematic review compares probiotics with antibiotics for managing gingivitis and periodontitis.


Probiotics, Autoimmune Disease, and Inflammation

| Researchers | PubMed | 2026 

A systematic review and meta-analysis examines oral probiotic and synbiotic supplementation across autoimmune diseases.

| X. Wang et al. | PubMed | 2024 

A review examines the emerging relationship between intestinal microbiota and autoimmune disease.

| L. Zeng et al. | PubMed | 2024 

A systematic review and meta-analysis evaluates gut microbiota-based therapies across autoimmune diseases.


Probiotics and Kidney Stones

| H. Taheri et al. | PubMed | 2024 

A review examines probiotics and herbal interventions for kidney stones and nephrolithiasis.


Probiotics and Atopic Dermatitis

| Researchers | PubMed / Springer | 2026 

An umbrella review evaluates systematic reviews and meta-analyses examining probiotics for atopic dermatitis and related allergic conditions in infants and children.

| Researchers | Journal of Allergy and Clinical Immunology: Global | 2026 

A systematic review and meta-analysis examines randomized trials of probiotics for eczema and atopic dermatitis in children and adolescents.

| Researchers | Indian Journal of Dermatology | 2025 

A systematic review and meta-analysis examines probiotic supplementation for adults with atopic dermatitis.

| Researchers | PubMed | 2023 

A systematic review and meta-analysis evaluates probiotic supplementation in adults with atopic dermatitis.

| Researchers | Pediatric Allergy and Immunology | 2020 

A network meta-analysis compares different probiotic strains used to treat pediatric atopic dermatitis.


Probiotics and Helicobacter pylori

| Researchers | Microbial Pathogenesis | 2026 

A meta-analysis of 28 randomized controlled trials evaluates probiotic monotherapy for reducing Helicobacter pylori colonization without antibiotics.


Probiotics and Oral Health

| Researchers | Frontiers in Oral Health | 2026 

An umbrella review of meta-analyses examines probiotic interventions for dental and oral health.

| Researchers | PubMed | 2025 

A systematic review evaluates randomized clinical trials investigating probiotics for enamel demineralization and cariogenic bacteria.

| Researchers | PubMed | 2023 

A systematic review investigates probiotics and oral health, including dental caries, periodontal disease, halitosis, mucositis and peri-implant conditions.


Probiotics and Obesity, Cholesterol, and Metabolic Health

| Researchers | Obesity Reviews | 2026 

A systematic review and meta-analysis examines probiotic and synbiotic supplementation and lipid levels among people with overweight and obesity.

| Researchers | Diabetes & Metabolic Syndrome | 2024 

A systematic review and meta-analysis evaluates probiotics, prebiotics, synbiotics and other microbiome-modifying therapies for metabolic syndrome.

| Researchers | Clinical Nutrition | 2021 

A meta-analysis of 26 randomized controlled trials involving 1,720 participants evaluates probiotics for people with overweight or obesity.

| Researchers | PubMed | 2021 

A systematic review and meta-analysis examines probiotic and synbiotic supplementation in adults with metabolic syndrome.

| Researchers | Current Atherosclerosis Reports | 2020 

A systematic review and meta-analysis examines probiotics and cardiovascular disease risk factors.

| Researchers | PubMed | 2019 

A systematic review and meta-analysis examines probiotics for overweight and obesity.


Probiotics and Fatty Liver Disease

| Researchers | PubMed | 2024 

A network meta-analysis compares different probiotic combinations for nonalcoholic fatty liver disease.

| Researchers | Expert Review of Gastroenterology & Hepatology | 2022 

A systematic review and meta-analysis evaluates randomized controlled trials of probiotics for nonalcoholic fatty liver disease.

| Researchers | PubMed | 2013 

An early meta-analysis examines probiotic treatment for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.


Probiotics and Constipation

| Researchers | Nutrients | 2022 

A systematic review and meta-analysis examines probiotics for constipation-predominant irritable bowel syndrome.

| Researchers | PubMed | 2017 

A systematic review and meta-analysis examines probiotic products for constipation in adults.

| Researchers | American Journal of Clinical Nutrition | 2014 

A systematic review and meta-analysis evaluates probiotics for functional constipation in adults.


Probiotics and Bacterial Vaginosis

| Researchers | PubMed | 2022 

A systematic review and meta-analysis evaluates probiotics for bacterial vaginosis.

| Researchers | European Journal of Pharmacology | 2019 

A systematic review and meta-analysis of 13 randomized clinical trials evaluates probiotics alone and in combination with antibiotics for bacterial vaginosis.
Retrieved from "https://wikidemocracy.us/index.php?title=Probiotics&oldid=17567"